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ABSTRACT 
 
Background: The persistence of latent viral reservoirs is a major roadblock to human 
immunodeficiency virus type 1 (HIV-1) cure development. Latent reservoirs harbour transcriptionally 
silent yet replication competent proviruses. However, the molecular mechanisms that govern HIV-1 
latency at the transcriptional level is unknown. Therefore, we hypothesize that HIV-1 subtype C (HIV-
1C) transmitted/founder (T/F) 5’ long terminal repeat (LTR) genetic variation may affect disease 
outcome.  
 
Methods: To address this, viral RNA was extracted from plasma samples obtained from 25 HIV-1 
infected patients from the HPP and FRESH acute infection cohorts (QIAamp® Viral RNA Mini Kit, 
Qiagen, Hilden, Germany). Viral RNA was reverse transcribed to DNA using SuperScript™ III One 
Step RT-PCR System with Platinum™ Taq DNA Polymerase (Invitrogen, Massachusetts, United 
States). Nested PCR was performed (Platinum® Taq DNA Polymerase High Fidelity PCR Kit 
(Invitrogen, Massachusetts, United States) and PCR products cloned into the pGL3 Basic plasmid. 
LTR/pGL3 recombinant plasmids were sequenced using BigDye Terminator v3.1 Sequencing Kit 
(Invitrogen, Massachusetts, United States) to confirm correct sequences. The LTR-pGl3 recombinant 
plasmids were transfected into Jurkat cells alone or co-transfected with either consensus (wild type) 
subtype C Tat (conTat) or autologous tat (autoTat) to determine the effect of LTR genetic variation on 
expression of a luciferase reporter gene.  
 
Results: Interestingly, our data demonstrate that basal transcription activity significantly differs 
between LTR variants. Specifically, patients harbouring the Sp1 III: G2A mutation demonstrated 
significantly lower transcription compared to the wild type LTR. Although conTat co-transfection 
increased the LTR activity for most of the LTR variants, the T/F virus LTR containing the TATA box 
mutation (TATAA  TAAAA) in combination with other LTR mutations was not induced.  
Interestingly, the transactivation activity of the autologous Tat was variable among patients. 
Specifically, the TATA box variant was marginally induced. Lastly, we observed that the majority of 
LTR variants were more responsive to stimulation by PMA as compared to TNF-α, SAHA and 
prostratin. Interestingly, our data demonstrate that autologous tat induced transcription positively 
correlated with viral load at transmission (p=0.0134, r=0.66) and at one-year post infection but was not 
significant (p=0.3905, r=0.26).  
 
 
xv 
 
Conclusion: These data suggest that the TATAA  TAAAA mutation in combination with other LTR 
mutations may reduce transcription activity. Taken together our data suggest that HIV-1 subtype C T/F 
viruses LTR genetic variation may modulate viral gene transcription and impact disease outcome. 
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CHAPTER 1: INTRODUCTION 
 
Since its discovery as the causative agent of acquired immunodeficiency syndrome (AIDS) in 1983 
(Barré-Sinoussi et al., 1983), human immunodeficiency virus (HIV) has become a global health 
pandemic. The recently published Joint United Nations Programme on HIV/AIDS (UNAIDS) 2019 
report documented that there were approximately 37.9 million individuals living with HIV, 1.7 million 
new HIV infections, and 770 000 AIDS-related deaths globally in 2018 (UNAIDS, 2019).  
 
The introduction of combination antiretroviral therapy (cART) has significantly reduced morbidity and 
mortality associated with HIV-1 infection (Collaboration, 2010, Perelson et al., 1997, Trickey et al., 
2017, UNAIDS, 2019). Specifically, cART successfully suppresses viremia to even below clinically 
detectable levels (20-50 copies HIV-1 RNA/mL plasma) in people living with HIV (PLHIV) who have 
access and are adherent to treatment (Gulick et al., 1997, Hammer et al., 1997, Perelson et al., 1997). 
Despite the ability of cART to suppress HIV replication, treatment interruption results in viral rebound, 
thus cART is unable to eradicate or cure HIV-1 infection (Chun et al., 2010, Davey et al., 1999). The 
failure of cART to cure HIV-1 infection is due to the establishment of stable HIV-1 latent reservoirs 
early in acute infection (Chun et al., 1998, Chun et al., 1997, Finzi et al., 1997, Siliciano et al., 2003b). 
HIV-1 latent reservoirs comprise a subset of resting memory CD4+ T cells that are infected with 
replication competent and yet transcriptionally silent HIV-1 proviruses (Chun et al., 1997, Finzi et al., 
1999, Persaud et al., 2000, Siliciano et al., 2003a). Therefore, latent reservoir remains the primary 
obstacle in the development of an effective HIV-1 cure. 
 
However, the mechanisms that govern HIV-1 latency have not yet been fully elucidated. Interestingly, 
several mechanisms of latency development have been proposed. Host chromatin compaction around 
the integrated HIV-1 proviral genome in non-dividing (inactive) cells has been associated with a state 
of viral latency. The host chromatin is associated with histone proteins that together form a functional 
unit called nucleosome. The chromatin configuration within the nucleosomes may either promote a 
state of viral transcription or viral latency. Actively transcribed genes are located within an open or 
relaxed state of chromatin called euchromatin. However, the heterochromatin configuration (tightly 
compacted chromatin configuration) is associated with viral latency (Jordan et al., 2003).  The 
heterochromatin configuration prevents the transcription factors (TFs) from accessing their respective 
transcription factor binding sites (TFBS). Therefore, this imposes a block on active gene transcription. 
However, this form of viral latency is reversed when infected cells become activated by 
 
2 
 
varying stimuli such as phorbol esters (eg. Phorbol myristate acetate) and tumor necrosis-alpha (TNF-
α) (Verdin et al., 1993). Viral latency is further enforced by two nucleosomes, nuc-1 and nuc-0 that are 
deposited on the integrated proviral LTR (Rafati et al., 2011, Van Lint et al., 1996, Verdin et al., 1993). 
Particularly, nuc-1 is positioned near the transcription start site and is located such that it impairs RNA 
polymerase II (RNA pol II) elongation (Verdin et al., 1993). The positioning of nuc-1 exerts a highly 
repressive effect on LTR transcription but this nucleosome is particularly disrupted during proviral LTR 
activation (Verdin et al., 1993).  
 
 Epigenetic modification such as histone acetylation and methylation significantly alter the chromatin 
and transcriptional state of the proviral genome. Hypoacetylation of the histone tails are associated with 
the latent proviral LTR (Coull et al., 2000, Jiang et al., 2007, Tyagi and Karn, 2007, Williams et al., 
2006). The recruitment of histone acetyltransferases (HATs) results in acetylation of the lysine residues 
of histone 3 (H3) and histone 4 (H4). The significance of the hyperacetylation of the lysine residues of 
H3 and H4 is noted by the inhibition of histone deacetyltransferases [(HDACs) enzymes that remove 
acetyl groups from the histone tails] that significantly increases the reactivation potential of the latent 
proviral LTR (Archin et al., 2014, Archin et al., 2009, Shirakawa et al., 2013). In addition, methylation 
of the lysine residues of H3 are associated with repression of the proviral LTR. Specifically, the 
trimethylation of H3 lysine residue 9 and lysine residue 27 induces proviral latency (du Chéné et al., 
2007, Friedman et al., 2011, Kim et al., 2011, Mateescu et al., 2008).  
 
A third mechanism that promotes proviral latency includes DNA methylation. The HIV-1 proviral 
transcription start site is flanked by two CpG islands that when methylated, induce transcriptional 
silencing of the proviral 5’LTR (Blazkova et al., 2009, Kauder et al., 2009).  Methylated CpG islands 
prevents the interaction between TFs such as NF-кB and Sp1 and their respective binding sites 
(Bednarik et al., 1991). One of the two CpG islands further contain a methyl binding domain protein-2 
(MBD2) that further represses transcription by the proviral 5’-LTR (Kauder et al., 2009). A fourth 
mechanism of viral latency is transcriptional interference. Transcriptional interference may occur via 
two mechanisms based on the polarity of the integrated viral genome. When the polarity  of the 
integrated proviral genome is the same as the host genome then interference occurs via an upstream 
RNA pol II that causes viral promoter occlusion and displaces the transcription factors at the viral 
promoter during RNA Pol II read-through (Greger et al., 1998, Lenasi et al., 2008). However, when the 
proviral genome is integrated in the opposite direction to the host genome then RNA pol II transcription 
complexes originating at different regions within the genome may collide and result in premature 
transcription termination (Han et al., 2008).  This further promotes a state of viral latency. However, 
the proposed mechanisms of viral latency explain the development of HIV-1 latency in part meaning, 
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the precise mechanism that modulates HIV-1 latency at the transcriptional level has not yet been fully 
elucidated. Therefore, the current study focuses on the impact of HIV-1 subtype C (HIV-1C) 
transmitted/founder (T/F) viruses LTR variation on disease outcome.  
 
The HIV-1 LTR is divided into three regions, the U3, R and U5 regions (reviewed in (Groen and Morris, 
2013). The U3 region is composed of the core promoter, enhancer and modulatory regions that play a 
central role in LTR’s ability to drive viral gene transcription (reviewed in (Groen and Morris, 2013). 
The structure and function of the 5’-LTR will be discussed in detail in the subsequent literature review 
(Chapter 2). Inter- and intra-subtype 5’-LTR genetic variation has been reported only during chronic 
infection where the virus has already diversified (Baar et al., 2000, Bachu et al., 2012, Boullosa et al., 
2014, Hunt et al., 2001, Jeeninga et al., 2000, Obasa et al., 2019, Scriba et al., 2002). Baar et al., (2000) 
demonstrated subtype specific differences in the LTRs of subtypes A through G. they demonstrated that 
subtypes B, D and F exhibited a second CTG motif located downstream of the TCF1-α which was not 
seen among the other subtypes (Baar et al., 2000). In addition, subtype C specifically exhibited the 3rd 
NF-кB binding site while subtype E specifically replaces one of the conserved canonical NF-кB binding 
site with a GABP binding site (Baar et al., 2000). This emphasizes the inter-subtype LTR genetic 
variation.  
 
Early studies (Hunt et al., 2001, Scriba et al., 2002) had reported that the HIV-1 subtype C circulating 
within South Africa exhibited the 4th NF-кB at a low frequency. Interestingly, a later study reported that 
subtype C viruses circulating within India contained the 4th NF-кB binding site and were inferred to be 
taking over the epidemic within India (Bachu et al., 2012). Furthermore, these viruses with the 4th-NF-
кB binding site were shown to be associated with a stronger transcriptional activity, enhanced 
replication fitness and higher viral loads when compared to the subtype C viruses with 3 NF-кB binding 
sites (Bachu et al., 2012). Specifically, Jeeninga et al., (2000) reported that the subtype E core promoter 
is more potent than the subtype B core promoter. Thus, demonstrating that inter-subtype genetic 
variation of the core promoter translates to differential transcription and replication activity. Taken 
together, these data demonstrate that intra-subtype 5’-LTR genetic variation may have implications for 
the transcription and replication capacity of the virus. The effect of genetic variation within the HIV-1 
LTR is discussed in detail in the subsequent literature review (Chapter 2).  
 
As aforementioned, previous studies investigated the functional variation of the HIV-1 LTR in chronic 
infection cohorts. However, in chronic infection most proviruses are defective (Bruner et al., 2016). On 
the other hand, the transmitter/founder (T/F) virus is the virus that is transmitted from a donor and 
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establishes infection in the new host (Haaland et al., 2009, Keele et al., 2008). Immediately following 
transmission, the pool of HIV-1 viruses circulating in the blood are homogenous (Keele et al., 2008). 
The homogenous character of the circulating viruses during acute infection is reported to be as a result 
of selective pressures that occur during transmission and establishment of the infection in the new host 
(Learn et al., 2002). 
 
 Interestingly, the data from our group and others (Carlson et al., 2014, Naidoo et al., 2017) show that 
the consensus like viruses for gag, nef and env sequences are selected for at transmission. Therefore, 
the data demonstrate that the viruses containing consensus like sequences for gag, nef and env are 
selected for at transmission and are transmitted to establish an infection in the next host (Carlson et al., 
2014, Naidoo et al., 2017). However, it is not known whether this is true for other parts of the HIV-1 
genome, more especially, the HIV-1 subtype C LTR that regulates viral gene transcription. 
Interestingly, the preliminary data from our group show intra-subtype HIV-1C T/F viruses LTR 
variation exists at transmission with viruses obtained from 2/25 (8%) of the patients exhibiting 4 NF-
кB binding sites instead of the usual 3 NF-κB binding sites (Shamara Naicker et al., unpublished). In 
addition, preliminary LTR sequences obtained from 14 out of 25 patients exhibited the A5T mutation 
within the Sp1 III binding site. This LTR genetic variation associated with a lower viral load. However, 
the effect of this genetic variation on the transcription activity of the T/F viruses 5’ LTR is not known. 
Understanding the impact of the 5’ LTR genetic variation on its transcription activity and disease 
outcome may guide the development of HIV cure or eradication strategies.  
 
1.1. Hypothesis 
 
It is hypothesized that HIV-1 subtype C T/F viruses LTR genetic variation may have an impact on the 
viruses’ transcriptional activity and may influence disease outcome in a cohort from South Africa. 
 
1.2. Aim 
 
The main aim of this project was to characterize the functional activity of the different HIV-1 subtype 
C T/F viruses LTR variants and to correlate this with markers of disease progression in an acute 
infection cohort of South Africans. 
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1.3. Objectives 
 
1.3.1 Clone and sequence the patient derived HIV-1C transmitted/founder (T/F) viruses LTR 
sequences from FRESH and HPP cohorts - to study functional differences between LTR 
variants. 
1.3.2 Determine the transcriptional activity of different HIV-1C T/F viruses LTR variants using a 
transcriptional assay.  
 
1.3.3 Determine the cell activation potential of the HIV-1 subtype C T/F viruses LTR variants using 
a transcriptional assay and stimulation with tumor necrosis factor-α (TNF-α), phorbol myristate 
acetate (PMA), suberoylanilide hydroxamic acid (SAHA) and prostratin.  
 
1.3.4 Correlate the HIV-1 LTR variants with markers of disease progression such as viral load and 
CD4 count. 
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CHAPTER 2: LITERATURE REVIEW 
 
2.1   Background 
 
The origin of human immunodeficiency syndrome (HIV) has been traced back to Africa from the early 
1920’s (Faria et al., 2014). The analyses of archived HIV positive blood samples provided evidence 
that the spread of HIV initiated through the transmission of the genetically similar simian 
immunodeficiency virus (SIV) (Faria et al., 2014). This transmission was from chimpanzees to the 
human population in Kinshasa, Congo (Faria et al., 2014). The widely accepted mechanism of 
transmission of SIV to the human population is believed to be as a result of Congolese communities 
that may have hunted, consumed or contacted SIV contaminated blood from the chimpanzees (Sharp 
and Hahn, 2011). The earliest confirmed case of HIV was traced to 1959 in Kinshasa from a blood 
sample obtained from an apparently healthy male (Science, 1998). The spread of HIV from Kinshasa 
to other geographical locations may be attributed to the expanding sex trade and migration dynamics 
within the Congo during that time (Faria et al., 2014, Wise, 2014). 
 
Although HIV had originated from Africa, it was assumed that HIV had begun in the United States of 
America (USA) as the first cases of AIDS were only documented in October 1980 to May 1981 in the 
USA. The cases of rare cancer diseases in the USA was critical to the progressive discovery of HIV as 
discussed henceforth. In June 1981, the Centers for Disease Control and Prevention Morbidity and 
Mortality Weekly Report (CDC’s MMWR) reported the occurrence of a rare lung condition known as 
Pneumocystis carinii pneumonia in 5 previously healthy young homosexual males. These 5 males were 
hospitalized in Los Angeles from October 1980 – May 1981 (CDC, 1981b). However, within months 
of diagnosis 2 out of the 5 homosexual males passed away. Pneumocystis carinii pneumonia is a disease 
that was known to be associated with severe immunosuppression, which occurred mainly in elderly 
individuals (Walzer et al., 1974). However, the occurrence of this disease in young individuals without 
the predisposition to immunosuppression was a rare incidence (CDC, 1981b).  
 
A month later, in July 1981, medical doctors in California and New York City reported 26 cases of a 
rare cancer disease known as Kaposi’s Sarcoma in homosexual men (CDC, 1981a). Notably, in July 
1981 an additional 10 cases of Pneumocystis carini pneumonia were identified in another group of 
homosexual males from Los Angeles (4 cases) and San Francisco (6 cases) (CDC, 1981a). Between 
May 1981 and July 1981, the number of  rare cancer disease cases in homosexual males had reached a 
total of 41 reported cases (Altman, 1981).  This disease was therefore associated with gay population. 
In the beginning of June 1982, the disease became known as gay-related immune deficiency (GRID) 
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because it had only been documented among the homosexual male population (CDC, 1982a). However, 
by the end of September 1982, the disease was also reported in 3 individuals with hemophilia, 36 
Haitians and 77 intravenous drug users (CDC, 1982b, CDC, 1982d). At this time, it became clear that 
the disease could become established in other population groups (CDC, 1982b, CDC, 1982d). In 
addition, it became clear that the disease could be acquired by coming into direct contact with 
contaminated body fluids. In September 1982, the CDC had termed the disease acquired 
immunodeficiency syndrome (AIDS) (CDC, 1982c).  
 
However, the viral agent responsible for the AIDS outbreak was unknown until May 1983 when 
scientists at the Pasteur Institute reported the discovery of the retrovirus,  Lymphadenopathy-Associated 
Virus (LAV), as the agent responsible for AIDS (Barré-Sinoussi et al., 1983). Subsequently, in 1984, 
scientist Luc Montagnier and colleagues at the USA National Cancer Institute (NCI) identified this 
retrovirus but called it the Human T-Lymphotropic virus II (HTLV-II) (Marx, 1984). In addition, they 
had confirmed that HTLV-II may likely be the cause of AIDS (Marx, 1984). In March 1986 these 
viruses were renamed human immunodeficiency virus (HIV), the known causative agent of AIDS 
(Case, 1986). 
 
 
 
  2.2.  Epidemiology 
 
2.2.1. The Role of Circulating Non-Human Primate Simian Immunodeficiency Virus (SIV) 
 
The global HIV-1 epidemic is due to the zoonotic transmission of SIV from chimpanzees. The 
diversfication of HIV-1 into four groups (Group M, N, O and P) is shown to be as a result of 
acrossspecies transmission event from different species of primates infected with their own species-
specific SIV (keele et al., 2006, Neel et al., 2010). The Phylogenetic analysis has demonstrated that the 
zoonotic transmission of non-human primate SIV to humans has occurred during at least 8 transmission 
events (Hahn et al., 2000, Sharp et al., 2001). Currrently, serological evidence shows that over 40 
species of non-human primate species are infected with a species specific virus. Approximately 90% of 
the non-human primate species have tested postive for a species specific SIV (Peeters et al., 2010). 
While the origin of HIV in the human population is known to be derived from the zoonotic transmision 
of SIV from chimpanzees, gorrilas and sooty mangabeys, other non-human primates (Colobus sp., 
mandrills, etc) may also be a source of transmitting their species specific SIV to the human population 
(Peeters et al., 2002). The human population in Sub-Saharan Africa is exposed to primates other than 
chimpanzees due to the hunting of bushmeat (Hahn et al., 2000).  
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The transmission of non-human primate SIVs to the human population may most likely be the result of 
human exposure to infected non-human primate blood (Hahn et al., 2000). Since the most likely 
trasnmisssion route is blood, hunters of primates are at increased risk for zoonotic transmission into the 
human population. The risk of zoonotic transmission to humans has increased with changes in the 
socioeconomic status of the Sub-Saharan population as well as with the increase in prevalence of non-
human primate SIVs. The increased market for bushmeat as a source of food and income supports the 
possibility of zoonotic transmission events into the human population (Asibey., 1974, Geist, 1988) . In 
additon, in vitro assays have shown that non-human primate SIVs other than chimpanzees can replicate 
efficiently in primary human lymphocytes (Georges-Courbot et al., 1998). This further supports that 
possibility that zoonotic transmission to the human population may result in productive infection in 
humans.  
 
 
Another factor to consider is whether any zoonotic transmission of non-human primate SIV from 
primates other than chimpanzees has been occuring (Peeters et al., 2010). A major concern is that a 
number of SIV strains may not be recognized by the standard HIV assays reslulting in a prolonged 
incbation period before the virus can be isolated or identified. This comes with the risk that newly 
circulating strains of SIV in humans may recombine with the circulating  HIV viruses already 
established in the human population possibly leading to a new epidemic (Bailes et al., 2003). 
 
2.2.2. HIV Epidemiology 
Human immunodeficiency virus was discovered as the causative agent of Aids in 1983 (Barré-Sinoussi 
et al., 1983) and has since then become a global health concern. The Joint United Nations Programme 
on HIV/AIDS (UNAIDS) 2019 report estimated that there were approximately 37.9 million individuals 
living with HIV, 1.7 million new HIV infections, and 770 000 AIDS-related deaths globally in 2017 
(UNAIDS, 2019). 
 
While Eastern and Southern Africa account for only 12% of the world’s population (Kharsany and 
Karim, 2016), they constitute the majority (approximately 54%) of global HIV-1 infections (UNAIDS, 
2019). Moreover, South Africa has a rapidly expanding epidemic (Karim and Karim, 2010) and 
constitutes 30% of the new HIV infections in Southern Africa (Figure 1) (UNAIDS, 2019). Thus, 
further highlighting the severity of the HIV pandemic in this region. 
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Figure 1. The distribution of HIV infections in Eastern and Southern Africa. The chart records the 
percentage contribution of each country within the Eastern and Southern regions. The percentage 
contribution of each country is marked by a specific colour that correlates with the respective country 
in the key presented below the chart. Specifically, the circles highlight that South Africa, marked by a 
silver colour, has the largest number of HIV infections (30%) in Eastern and Southern Africa. 
Reproduced with modifications from the UNAIDS 2018 report.  
 
 
Thus far HIV has been characterised into two distinguished types, human immunodeficiency virus type 
1 (HIV-1) and human immunodeficiency virus type 2 (HIV-2) (Clavel et al., 1986). The HIV-1 and 
HIV-2 exhibit similar genome organisation with specific genetic variation that sets them apart  (Fletcher 
et al., 1996, Schulz et al., 1990, Zagury et al., 1988) and these differences will be highlighted as the 
review continues. In addition, they are distinguished by their geographical spread. The HIV-2 is largely 
restricted to West Africa (De Cock et al., 1993), while HIV-1 is globally distributed and accounts for 
90% of the global HIV infections (Hemelaar, 2012). HIV-1 is diversified into four distinct groups 
namely, group M (Main), N (New), O (Outlier) and P (Ayouba et al., 2000, De Leys et al., 1990, Gürtler 
et al., 1994, Simon et al., 1998). Group M predominantly accounts for the majority of global HIV-1 
infections and is further diversified into nine genetically distinct subtypes, subtypes A-D, F-H, J and K 
(Hemelaar et al., 2011). Recombination events between pure subtypes results in the formation of new 
strains of HIV-1 classified as circulating recombinant forms (CRFs) (Eliuk et al., 2011). A recombinant 
strain is defined as a CRF based upon its appearance in at least 3 infected subjects in the absence of an 
epidemiological link (Robertson et al., 2000). Thus far, at least 96 CRF’s have been documented in the 
Los Alamos HIV database (www.hiv.lanl.gov). 
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Figure 2. HIV diversification. The left side of the diagram characterizes HIV into two types, and further 
classifies HIV-1 into groups and subtypes. The HIV is divided into two different types, HIV-1 and HIV-
2. The HIV-1 is divided into 4 groups, Group M (Major), Group N (New), Group O (Outlier) and Group 
P. Group M is further divided into 9 subtypes A-D, F-H, J and K and 96 circulating recombinant forms 
(CRFs) of HIV (www.hiv.lanl.gov). Reproduced with modifications from https://www.hiv.uw.edu/pdf/ 
screening-diagnosis/epidemiology/core-concept/all 
 
 
The HIV-1 subtypes are unevenly distributed globally (Figure 3). Subtype A is predominant within 
Central and East Africa (Buonaguro et al., 2007), while subtype B predominates North and South 
America, Australia and West and Central Europe (Hemelaar et al., 2011). Subtype D dominates North 
Africa and the Middle East whereas subtype F is established in South and Southeast Asia (Hardy, 2017). 
Subtype G is predominantly found in West and Central Africa (Hardy, 2017). The least common HIV-
1 subtypes, subtype H, J and K persist stably at low levels in the population (Castley et al., 2017) and 
is geographically dominant in Africa and the Middle East (Hardy, 2017). Although the CRF’s are 
distributed worldwide, three CRF’s contribute significantly to the HIV-1 epidemic, CRF01_AE, 
CRF_02AG and CRF07_BC (Lau and Wong, 2013). The CRF02_AG is predominantly located in West 
and Central Africa while CRF01_AE is dominant within Southeast Asia (Bbosa et al., 2019, Hemelaar 
et al., 2011). In addition, CRF01_AE and CRF07_BC are predominate in china (Bbosa et al., 2019). 
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Figure 3. The global distribution of HIV-1 subtypes. Each subtype is represented by a different colour 
as demonstrated by the key in diagram. Subtype B represented by the orange colour dominates in North 
and South America. However, subtype C represented by the blue colour is seen to dominate Eastern, 
Southern Africa and India. Furthermore, the pie chart in the figure indicates that subtype C contributes 
to approximately 50% of the global HIV-1 pandemic while the other 50% of the HIV-1 pandemic is 
divided among the remaining HIV-1 subtypes (Reproduced from (Hemelaar et al., 2011).  
 
 
On the other hand, HIV-1 subtype C is predominant in Sub-Saharan Africa and India (Hemelaar et al., 
2011, Venner et al., 2016). The HIV-1 subtype C accounts for approximately 50% of the current 
worldwide infections (Figure 3) (Bbosa et al., 2019, Buonaguro et al., 2007, Castley et al., 2017, 
Hemelaar et al., 2011, Venner et al., 2016). Therefore HIV-1 subtype C is the focus of this study. As 
aforementioned, HIV-1 and HIV-2 are similar with a few genetic traits that set them apart. Therefore, 
the rest of this project proposal will refer to HIV-1 and only highlights differences between HIV-1 and 
HIV-2. 
 
 
2.3   The Virology of HIV-1 
 
Human immunodeficiency virus type 1 is classified into the genus lentivirus belonging to the family 
Retroviridae (Coffin, 1992). The HIV-1 genome is approximately 9.7 Kb long (Hahn et al., 1984) 
consisting of two genetically identical single stranded RNA genomes, each bordered by an incomplete 
long terminal repeat (LTR) on both the 5’- and 3’ end of the genome (Coffin, 1992, Montagnier, 1999). 
Briefly, the 5’ end LTR of the RNA genome lacks the U3 region while the 3’ end LTR of the RNA 
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genome lacks the U5 region. The structure and the function of the full LTR element is discussed in 
detail in the subsequent sections since it is the focus of this study. 
 
 
 
Figure 4. The HIV-1 genome. The HIV-1 genome is approximately 9.7 Kb long. The 5’and 3’-LTR 
flanks the entire HIV-1 genome. The rectangles indicate the reading frames of the HIV-1 genes. The 
structural genes include gag (brown), pol (yellow) and env (blue). The HIV-1 accessory and regulatory 
genes vif, vpr, vpu and nef are represented by pink rectangles. The two HIV-1 regulatory genes tat and 
rev also represented by pink colour.  Reproduced from (Waheed and Freed, 2010). 
 
 
The HIV-1 genome consists of  9 genes, which are categorized into 3 structural genes, 4 accessory genes 
and 2 regulatory genes (Figure 4) (Gallo et al., 1988, Stevens and Miller, 2016). The structural genes 
consist of: gag, pol and env, the accessory genes comprise the: vif, vpr (vpx in the case of HIV-2); vpu 
and nef while the regulatory genes comprise of the tat and rev (Gallo et al., 1988, Stevens and Miller, 
2016). 
 
2.4   The HIV-1 Proteome 
 
Although the HIV-1 genome has a small genome size with only 9 genes, it codes for a total of 16 viral 
proteins. The gag gene encodes for the p55 precursor protein that is cleaved to form four main structural 
proteins (Fields et al., 1996, Stevens and Miller, 2016). These include the symmetrical p17 matrix 
protein (MA) of the outer core membrane, the canonical p24 capsid protein (CA protein), the p7 
nucleocapsid protein and a p6 protein (Fields et al., 1996, Henderson et al., 1992, Mervis et al., 1988). 
The pol gene encodes a precursor protein that is cleaved to produce 4 viral enzymes, which include 
Protease (PR), Reverse transcriptase (RT), RNAse H and Integrase (IN) (Ellegård, 2018, Fields et al., 
1996, Stevens and Miller, 2016). The env gene encodes the gp160 precursor protein that is cleaved to 
form glycoprotein gp120 and glycoprotein gp41 (Fields et al., 1996, Stevens and Miller, 2016). 
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In addition to the structural proteins, HIV-1 encodes two important regulatory proteins which include 
the Transactivator of transcription (Tat) and the regulator of expression of virion (Rev) from the tat and 
rev genes, respectively (Gallo et al., 1988). Lastly, the accessory genes nef, vpu, vpr and vif codes for 
the negative regulating factor (Nef), viral infectivity factor (Vif), virus protein unique (Vpu) (or VpX 
in terms of HIV-2) and virus protein r (Vpr) (Gallo et al., 1988).  
 
2.5   The HIV-1 Replication Cycle 
 
The HIV-1 replication cycle will be briefly discussed with the aim of highlighting the role of the viral 
promoter, 5’ LTR. The HIV-1 replication cycle is characterised into two phases, the early phase and the 
late phase (Tozser, 2003). The early phase of HIV-1 replication encompasses the attachment, entry, 
fusion and uncoating, reverse transcription, nuclear import and integration (Tozser, 2003). The late 
phase of HIV-1 replication is composed of the final steps which include viral gene transcription, 
assembly and budding (Tozser, 2003). 
 
2.5.1   Attachment and Entry 
 
The HIV-1 replication cycle begins with the binding of the mature virions to the target host cell. The 
mature virions successfully binds to the CD4 receptor of the host susceptible cell via its gp120 that 
project from the surface of the virions (Dalgleish et al., 1984, Klatzmann et al., 1984). The cellular 
attachment of gp120 to the host CD4 receptor induces a conformational change in the gp120 protein. 
The co-receptor binding sites of gp120 bind the co-receptors CXCR4 or CCR5, resulting in a more 
stable two-pronged attachment (Choe et al., 1996, Dragic et al., 1996, Friedman et al., 2007, Wu et al., 
1996). This further induces a conformational change in the gp41 protein resulting in the exposure of the 
fusion peptide (Chan et al., 1997). The gp41 fusion peptide penetrates the host cell membrane thus 
tethering the viral envelop close to the cell membrane (Gallaher, 1987, Gallo et al., 2003, Liu et al., 
2010). Consequentially, the gp41 fusion peptide creates a membrane fusion pore in the host cell 
membrane that facilitates the entry of the viral core into the host cell (Chan et al., 1997). 
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2.5.2   Uncoating 
 
Although uncoating is an important step in HIV-1 replication cycle since it makes viral RNA genome 
available for viral DNA synthesis, it is poorly understood. One theory proposes that viral core dis-
assembles immediately after cell entry making viral RNA available for reverse transcription to take 
place in the cytoplasm within the reverse transcription complex (RTC) (Fassati and Goff, 2001, 
Karageorgos et al., 1993, Miller et al., 1997). While the other theory proposes that uncoating occurs 
during viral core trafficking through the cytoplasm or once it has reached the nuclear pore complex 
(NPC), suggesting that reverse transcription occurs within the viral core (Arhel et al., 2007, Hulme et 
al., 2011, Lukic et al., 2014, Pawlica and Berthoux, 2014, Xu et al., 2013, Zhou et al., 2011). The 
subsequent steps that are linked to the first theory of transcription will be discussed in this dissertation. 
 
2.5.3   Reverse Transcription 
 
As aforementioned, following uncoating the reverse transcription of the viral RNA takes place 
immediately within the reverse transcriptase complex (RTC). The reverse transcriptase complex (RTC) 
contains the enzyme reverse transcriptase and the two single stranded HIV-1 RNA genome, IN, Vpr, 
MA and CA and cellular components such as dNTPs (Fassati and Goff, 2001, Iordanskiy et al., 2006, 
Nermut and Fassati, 2003). During the microtubule-based transport to the nucleus, the viral single-
stranded RNA genome is reverse transcribed into a double helix RNA/DNA hybrid complementary 
(c)DNA within the RTC (Bukrinskaya et al., 1998, McDonald et al., 2002). Simultaneously, the viral 
RNase H degrades the viral RNA while the host DNA polymerase synthesizes a complementary DNA 
strand to complete the synthesis of double stranded HIV-1 DNA. Following the synthesis of the 
complete HIV-1 double stranded DNA molecule, the RTC matures into the pre-integration complex 
(PIC) (Iordanskiy et al., 2006). The PIC comprises the HIV-1 DNA, IN associated viral proteins such 
as IN, NC and Vpr (Bukrinsky et al., 1992, KARAGEORGOS et al., 1993, Miller et al., 1997) and 
cellular proteins such as lens epithelium derived growth factor p75 (LEDGF/p75) (Cherepanov et al., 
2003) and Transportin SR2 (TRN-SR2)  (Christ et al., 2008). 
 
2.5.3.1.   Synthesis of the Full Length LTR 
 
The HIV-1 LTR is located at both the 5’and 3’ end of the HIV-1 genome. The LTR is divided into three 
regions namely the Unique 3 (U3), Repeat (R) and Unique 5 (U5) regions. The U3 region consists of 
the enhancer and promoter region while the R region consists of the initiation and termination sites for 
reverse transcription. As aforementioned, the 5’ LTR of HIV-1 RNA genome lacks the U3 region while 
 
15 
 
the 3’ LTR lacks the U5 regions (Delviks-Frankenberry et al., 2011). The synthesis of the full length 
LTR occurs via a strand transfer mechanism in sequential steps (Coffin et al., 1997) (Figure 5).   
 
The plus strand single stranded RNA genome serves as a template for the synthesis of a complementary 
minus strand of DNA. Reverse transcription initiates near the 3’end of the 5’LTR when the tRNA base 
pairs to the complementary Primer Binding Site (PBS) (Step 1). The enzyme RT then synthesizes the 
minus strand DNA by transcribing the U5 and R regions (Step 2). The newly synthesized minus strand 
DNA can then initiate the first jump and transfer to the 3’end of the plus strand RNA (Step 3). During 
the first strand transfer, the R region of the minus strand DNA base-pairs to the R-region of the plus 
strand RNA. Minus strand DNA synthesis then continues in the 3’to 5’direction when RT transcribes 
the U3 region adjacent to the R region and, continues transcribing the minus strand DNA until the 5’U5 
and R region are transcribed for the second time (Step 4).  
 
Upon synthesis of the minus DNA strand, RNase H subsequently degrades the plus strand template 
RNA except for the fragment of RNA that is annealed to the polypurine tract (PPT) at the 5’end of the 
3’-U3 region (Step 5). This RNA fragment acts as a primer for RT of the second strand of DNA which 
is the plus strand of DNA. Using the minus strand of DNA as a template, RT extends the plus strand 
DNA by transcribing the 3’Region and U5 region (Step 6). Following this, the second jump of DNA 
occurs in which the newly synthesized plus strand of DNA transfers to the 5’end of the minus strand 
DNA by base pairing with the R and U5 region (Step 7). DNA synthesis then proceeds in both directions 
to synthesize two complete and complementary double strands of DNA with the full length 5’and 3’LTR 
(Step 8).  
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Figure 5. Synthesis of the full length LTR. Step 1: tRNA binds to the PBS on the 5’-U3 region. Step 
2: RT transcribes the 5’U3 and R region to produce a minus strand DNA. Step 3: Minus strand DNA 
makes its first jump and binds to the 3’R region. Step 4: RT then extends the minus strand DNA in the 
3’  5’direection. Step 5: RNase H degrades the plus strand RNA template while leaving a short 
fragment of the plus strand RNA that remains bound to the PPT of the 5’ end of the 3’LTR. Step 6: RT 
then uses the minus strand DNA as a template to extend the fragment of RNA and synthesize the plus 
strand DNA in the 5’  3’direction. Step 7: Plus strand DNA then makes the second jump and binds 
to the 5’U3R region. Step 8: RT then extends the both the minus and plus strand of DNA to synthesize 
the full length 5’and 3’LTR. Reproduced with modifications from (Zhang et al., 2014). 
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2.5.4    Nuclear Import and Integration 
 
The TRN-SR2 protein mediates the transport of the PIC from the cytoplasm into the nucleus (Christ et 
al., 2008). The TRN-SR2 interacts directly with the viral IN through the IN catalytic core domain (CCD) 
and the IN C-terminal domain (CTD) (De Houwer et al., 2012). The IN CCD dimerizes with the IN 
CTD and the CCD-CTD dimers binds to the TRN-SR2 (De Houwer et al., 2012, Tsirkone et al., 2017). 
Integrase further interacts with the TRN-SR2 by binding to the HEAT proteins of TRN-SR2 (Tsirkone 
et al., 2017). This ultimately facilitates the migration of the PIC through the nuclear pore into the 
nucleus. Upon arrival of the PIC complex at the nucleus, TRN-SR2 binds to the Ras-related nuclear 
protein (Ran) to facilitate the release of the PIC into the nucleus (Taltynov et al., 2013).  
 
Once inside the nucleus, LEDGF/p75 tethers the PIC to the host (Cherepanov et al., 2003). The viral 
IN catalyses the integration of the viral double stranded DNA into the host genome through two 
processes (Engelman et al., 1991, Pauza, 1990, Vink et al., 1991). The integration process begins in the 
cytoplasm, where the IN catalytically removes the di-nucleotides (GT) from the 3’ end of both ends of 
the LTR to produce active 3’-OH groups at the 3’-ends of the LTR (Engelman et al., 1991, Fujiwara 
and Mizuuchi, 1988, Pauza, 1990, Roth et al., 1989, Vink et al., 1991). Once inside the nucleus, the 3’-
OH groups of the HIV-1 DNA initiate a nucleophilic attack on the host DNA to facilitate the stable 
insertion of the viral DNA into the host chromatin (Brown et al., 1989, Engelman et al., 1991, Fujiwara 
and Mizuuchi, 1988, Pauza, 1990, Vink et al., 1991). The gaps are then repaired by the host enzyme, 
ligase to form a stable integrated viral DNA, referred to as provirus.(Guth and Sodroski, 2014). This 
step occurs in the nucleus of the infected host cell. Once the HIV-1 genome is integrated into the host 
chromosome then it is referred to as provirus (proviral DNA). 
 
2.5.5    Viral Gene Expression 
 
The proviral DNA serves as a template for the transcription of HIV-1 genes (Guth and Sodroski, 2014). 
Viral gene transcription is driven by the LTR, which will now be discussed in detail since it is the focus 
of this study.  
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2.5.5.1    The Structure and Function of the HIV-1 LTR 
 
The HIV-1 DNA genome is flanked at both the 5’ and 3’ end by the LTR, which is approximately 640 
bp in length (reviewed in (Groen and Morris, 2013, Mbonye and Karn, 2014). The LTR of the DNA 
genome is divided into 3 distinguished regions, the U3, R and U5 regions. The U3 region is further 
divided into 3 domains that promote positive sense transcription, namely the core promoter, core 
enhancer and modulatory domain (Gaynor, 1992, Pereira et al., 2000) (Figure 6). The core promoter 
consists of various transcription factor binding sites including three tandem Sp1 binding sites, TATA 
box and an enhancer box (E-box) (Jones et al., 1986, Jones and Peterlin, 1994). Interestingly, the TATA 
box in subtype E viruses is mutated to contain a TAAAA sequence instead of the TATAA sequence 
described for subtype B and C (Bachu et al., 2012, Montano et al., 1998) In addition, the initiator site 
at the transcription start site is located within the core promoter (Groen and Morris, 2013, Mbonye and 
Karn, 2014, Qu et al., 2016).  
 
 
Figure 6. Structure of the full length 5’-LTR. The HIV-1 genome is ~~9.7 Kb long and consists of 9 
genes (gag, pol, env, vif, vpr, vpu, env, tat, rev and nef) that are flanked on both sides by the LTR. The 
3’and 5’LTR are identical at the structural and nucleotide level. The 5’LTR is divided into the U3, R 
and U5 region. The U3 region is divided into the modulatory domain, core enhancer domain and core 
promoter domain. The modulatory domain includes the TFBS such as AP1 (shown by the maroon oval), 
NFAT (shown by a blue circle) while the core enhancer consists of the NF-кB binding sites that vary 
in copy number depending on the subtype. Almost all subtypes consist of two conserved canonical NF-
кB binding sites (shown by the orange rectangles) however subtype E which consists of only one. 
Subtype C on the other hand consists of an additional 3rd NF-кB binding site (designated C-NF-кB and 
shown by a red rectangle). The core promoter domain consists of three tandem sp1 binding sites (shown 
by the purple diamonds) and a TATA box (shown by the maroon hexagon). The imitator site located in 
the core promoter is indicated by the arrow and +1 
 
 
 
19 
 
The core enhancer has been understood to typically contain 2 highly conserved NF-ĸB binding sites. 
However, NF-ĸB binding sites vary in number depending on the subtype being examined (Baar et al., 
2000, Bachu et al., 2012, Verhoef et al., 1999). A majority of subtypes consists of 2 canonical and 
conserved NF-кB binding sites whereas subtype E consists of only one NF-к binding site (Baar et al., 
2000, Jeeninga et al., 2000). Notably, subtype C exclusively consists of an additional third NF- кB 
binding site and (Bachu et al., 2012, Montano et al., 1997), subtype C viruses with an insertion of a 4th 
NF-кB binding site has also been described (Bachu et al., 2012) (Figure 6). The modulatory region 
consists of transcription factor binding sites located upstream of the enhancer element. These 
transcription factor binding consist of the CCAAT/enhancer binding protein (C/EBP), lymphocyte 
enhancer factor (LEF-1), nuclear factor of activated T cells (NFAT) and negative regulatory element 
(NRE) (Henderson et al., 1995, Shaw et al., 1988, Tesmer et al., 1993). 
 
2.5.5.2      The Function of Host Cellular Factors in Basal Transcription 
 
Following integration of the HIV-1 DNA, viral gene expression is mediated via the action of cellular 
and viral proteins that bind to the transcription factor binding sites (TFBS) on the core promoter, 
enhancer domains and modulatory region (Fields et al., 2007, Hunt et al., 2001). The HIV-1 gene 
expression consists of two phases, the early phase and late phase of transcription. During the early phase 
of transcription, the host cellular factors inclusive of NF-кB and Sp1 and Tata Binding Protein (TBP), 
bind to the core modulatory region, core enhancer and promoter region to initiate gene expression (Kao 
et al., 1987, Yedavalli et al., 2003).  The core promoter specifically initiates viral gene transcription and 
is sufficient for low levels of gene expression, However, the interaction between the cellular factors and 
the core modulatory and enhancer region is required to further stimulate the productive levels of basal 
gene transcription.   
 
In the modulatory region, the cellular transcription factor, nuclear factor of activated T cells (NFAT), 
plays a significant role in regulating HIV-1 transcription. In the inactive form, NFAT transcription 
factors remain sequestered and phosphorylated within the cell cytoplasm. However, upon T-cell 
activation, the calcium-calmodulin-dependent phosphatase calcineurin dephosphorylates and activates 
NFAT (Pessler and Cron, 2004). This subsequently leads to the translocation of the NFAT factors from 
the cytoplasm to the nucleus as well as the activation of genes containing the NFAT binding sites 
(Pessler and Cron, 2004). Although NFAT can bind to the NFAT binding site in the modulatory region, 
this is a low affinity interaction. Interestingly, NFAT factors bind with high affinity to the NF-kB 
binding sites in the enhancer region and is one of the significant binding sites for NFAT mediated HIV-
1 gene transcription (Cron et al., 2000). 
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In the activated form, NF-kB is a dimer composed of p65/p50 subunits (Baeuerle and Baltimore, 1989, 
Ballard et al., 1992, Ghosh et al., 1990, Kieran et al., 1990, Nolan et al., 1991, Ruben et al., 1992). 
However, when a cell is inactivated (in a resting state) the p65 NF-kB subunit is repressed by IkB while 
the p50 subunit circulates freely in the cell cytoplasm (Baeuerle and Baltimore, 1988, Ganchi et al., 
1992, Inoue et al., 1992, Nolan et al., 1991, Sen and Baltimore, 1986, Zabel and Baeuerle, 1990). 
Activated HIV-1 infected host cells relieve the restriction on p65 thus allowing p65 to dimerize with 
p50 and form NF-kB complexes (Nabel and Baltimore, 1987). The NF-kB is translocated to cell nucleus 
from the cytoplasm and, binds to the NF-kB TFBS on the core-enhancer domain of the 5’-LTR (Lenardo 
and Baltimore, 1989, Sen and Baltimore, 1986). 
 
One of the mechanisms via which the NF-kb and NFAT transcription factors modulates HIV-1 LTR 
driven transcription is through host chromatin modification. Host activating factors such as NF-kB and 
NFAT function to recruit histone modifiers such as histone acetyltransferases that modify lysine 
residues on histone 3 and histone 4 (Cron et al., 2000, Okamura et al., 2000, Zhong et al., 2002). This 
further modifies chromatin to an open configuration that exposes the transcription binding sites to 
additional host and viral transcription factors (reviewed in (Mbonye and Karn, 2014, Schiralli Lester 
and Henderson, 2012).  
 
The core promoter specifically initiates viral transcription. As aforementioned, the core promoter 
consists of the TATAA element and three tandem Sp1 binding sites, Sp1 I, Sp1 II and Sp1 III. Together, 
the TATAA element and the Sp1 binding sites function to initiate viral gene transcription (Roebuck and 
Saifuddin, 1999). The TATAA element binds the protein complex known as the transcription factor 
(TF) IID that is composed of the TATA binding protein (TBP) and multiple TBP associated factors 
(TAF) (Majello et al., 1998). The TBP plays a critical role in initiating the formation of the preinitiation 
complex for viral gene transcription (Pendergrast et al., 1996). The binding of cellular Sp1 transcription 
factors to the three tandem Sp1 sites on the HIV-1 core promoter activates the Sp1 sites. The activated 
Sp1 sites enhances the assembly of the preinitiation complex (Harrich et al., 1989). The preinitiation 
complex is stabilized by transcription factor (TF) IIA and TFIIB and is further completed by the 
recruitment of RNA Polymerase II-TFIIF, TFIIE and TFIIH (Thomas and Chiang, 2006). This promotes 
the initiation of transcription by the viral promoter, the 5’-LTR 
 
Following the initiation of transcription, the RNA polymerase II becomes regulated by the negative 
elongation factor (NELF) that inhibits the synthesis of complete (long) gene transcripts (Ping and Rana, 
2001). Therefore, although the LTR activity is efficiently initiated, the LTR is inhibited from producing 
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full length functional gene transcripts by NELF (Kao et al., 1987). The production of short abortive 
gene transcripts is mediated by the Inducer of Short Transcripts (IST) region located downstream from 
the transcription start site (Pessler and Hernandez, 1998, Sheldon et al., 1993). The newly synthesized 
abortive mRNA transcripts undergo splicing to remove the intronic regions of the early mRNA 
(Daelemans et al., 1999, Purcell and Martin, 1993). These multiple spliced mRNA transcripts encode 
the two regulatory genes, tat and rev. The multiple spliced mRNA transcripts are then exported to the 
cytoplasm for translation into the Tat and Rev proteins and, are then shuttled back to the nucleus.  
 
2.5.5.3      Tat Induced Viral Gene Transcription 
 
Although transcription has been initiated at this point, RNA Pol II is unable to elongate efficiently 
resulting in a paused transcription that produces short gene transcripts. However, Tat is synthesized in 
the cytoplasm and localizes to the nucleus where it functions as a strong activator of transcription (Raha 
et al., 2005). The Tat binds to the TAR RNA located in the R-region of 5’-LTR (Raha et al., 2005). The 
interaction between Tat and TAR enables Tat to recruit the co-factor positive transcription elongation 
factor b (P-TEFb) (Wei et al., 1998, Zhu et al., 1997). The P-TEFb is composed of two subunits namely, 
cyclin T1 and CDK9 (Wei et al., 1998, Zhu et al., 1997). The CDK9 subunit of P-TEFb phosphorylates 
the c-terminal domain of RNA Pol II and activates RNA Pol II to synthesize functional gene transcripts 
(Kim et al., 2002). The synthesis of Tat activates the Tat-dependent mechanism of LTR and increases 
the efficiency of gene expression resulting the formation of primary full length viral gene transcripts 
called pre-mRNAs (Karn, 2000). 
 
The primary pre-mRNA transcript can then either undergo single splicing or remain unspliced 
(Saltarelli et al., 1996). The single spliced mRNAs are translated into the Env, Vpu, Vpr and Vif viral 
proteins. While the unspliced viral transcripts are destined to be translated into the Gag or Gag-Pol 
polyprotein, or alternatively are packaged into the newly synthesized virions as the viral genome. The 
next step in viral gene expression is the export of the single spliced and unspliced viral gene transcripts 
that is mediated by the Rev regulatory protein that was synthesized during early phase of transcription. 
The single spliced and unspliced mRNAs are intron containing transcripts that consist of a Rev 
Response Element (REV) within the intronic region (Cullen, 2000, Cullen, 2003, Malim et al., 1989). 
Rev binds to the RRE and multimerizes resulting in the recruitment of nuclear factors such as CRM1 
and Ran-GTP. These nuclear factors then associate with the Rev-RRE complex to from a Rev-RRE-
CRM1-RanGTP RNA complex that aids the transport of the mRNAs to the cytoplasm through the 
nuclear pore complexes (Suhasini and Reddy, 2009). The mRNAs are released into the cytoplasm 
through the conversion of RanGTP to RanGDP that results in dissociation of the complex.  
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2.5.6    Assembly and Budding 
 
In the cytoplasm, the translation of the single spliced or unspliced transcripts results in the production 
of Gag, Gag-Pol, Vpr and Vif viral proteins. Upon the completion of viral proteins translation, viral 
proteins and the unspliced viral RNA that functions as the viral genome, then assemble into immature 
virions at the cell membrane (Guth and Sodroski, 2014). During assembly, host proteins such as tumor 
suppression gene 101 assist the assembly process to produce the immature virions. Viral budding occurs 
at the cholesterol rich plasma membrane. The process of budding is aided by the viral protein Vpu and 
the immature virions then bud through the host cell thus acquiring a viral envelope and then undergo 
maturation process to form matured virions (Fanales-Belasio et al., 2010). 
 
2.6.    The Impact of Genetic Variation in the 5’-LTR 
 
Genetic variation within the LTR may largely be due to the error prone reverse transcriptase that 
introduces nucleotide changes during reverse transcription (Shah et al., 2014). Genetic variation within 
the transcription binding sites alters the interaction of the transcription factors with their binding sites 
in the LTR (Jeeninga et al., 2000). This may consequentially alter the LTR mediated transcription. 
 
Previously, studies have investigated the effect of inter- and intra-subtype variation on disease outcome. 
Subtype B consists of 2 identical and conserved NF-кB binding sites (Bachu et al., 2012, Qu et al., 
2016). Although most viral subtypes share this characteristic, two exceptions include subtype AE and 
subtype C (Bachu et al., 2012). While subtype AE has only one NF-кB binding site (Jeeninga et al., 
2000, Montano et al., 1998), subtype C contains at least three NF-кB binding sites (Bachu et al., 2012). 
A majority of subtype C viruses exhibit three NF-кB binding sites while a small proportion of subtype 
C viruses contain a fourth NF-кB binding site (Bachu et al., 2012, Hunt and Tiemessen, 2000). 
Moreover, the occurrence of subtype C viruses with only two NF-кB binding sites have also been 
described (Bachu et al., 2012, Hunt et al., 2001, Scriba et al., 2001). The subtype C viruses consisting 
of three NF-кB binding sites have been correlated with higher transcriptional activity as compared to 
subtypes with one or two NF-кB binding sites (Bachu et al., 2012, Montano et al., 1998, Qu et al., 
2016). 
 
Montano et al., (1998) had shown that the HIV-1 subtype AE LTR, which contains one NF-кB binding 
site was less inducible upon TNF-α stimulation compared to the prototype subtype B. Therefore, the 
inter-subtype variability in the number of NF-кB binding sites may impact the replication rate of the 
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virus (Montano et al., 1998). In another study, Jeeninga et al., (2000) showed a correlation between the 
number of NF-кB binding sites and the degree of LTR activity. Consistent with Montano et al., the 
results reported by Jeeninga et al., indicated that the subtype AE which, contains one NF-кB binding 
site was the least activated with TNF-α as compared to subtype B, which contains two NF-кB binding 
sites. In addition, subtype C exhibited a greater degree of activation as compared to subtype B and AE 
(Jeeninga et al., 2000). Therefore, the presence of additional NF-кB binding site may confer an 
increased transcriptional and replicative ability to the virus.  
 
As aforementioned, subsequent studies have shown intra-subtype variability. The occurrence of 
insertions in the Mozambican and Brazilian HIV-1 subtype C LTR generated an additional NF-кB 
binding site (Boullosa et al., 2014). Interestingly, insertions found within the Brazilian HIV-1 subtype 
C LTR was linked to the presence of an additional RBE III binding site (Boullosa et al., 2014). These 
findings were demonstrated in isolates obtained from patients that failed to respond to therapeutic 
intervention (Boullosa et al., 2014).  
 
In addition to the variation observed within the NF-кB binding sites, studies have also investigated 
variation within the Sp1 binding sites. Qu et al. has demonstrated that the Chinese subtype B 5’-LTR 
exhibits variation in the Sp1 binding site and NF-кB binding site is linked to a variation in the viruses’ 
ability to drive viral gene transcription. Furthermore, in another study aimed at establishing a link 
between LTR sequence variation and disease progression, it was found that a mutation in the Sp1 site 
III that produces a C to T alteration at position 5 results in an increase in disease progression 
(Nonnemacher et al., 2004). 
 
 
2.7   The Bottleneck Theory  
 
A majority of global HIV-1 infections are as a result of heterosexual transmission (Joseph et al., 2015). 
Approximately 80% of new heterosexual HIV-1 infections are initiated by a single infecting viral 
variant termed the transmitted/founder (T/F) virus (Joseph et al., 2015). The heterosexual transmission 
of HIV-1 is distinguished by a stringent genetic bottleneck (Carlson et al., 2014). 
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Figure 7. A bottleneck of viral quasispecies exists at transmission. A chronically infected HIV-1 
individual contains a quasispecies of HIV-1 variants. The quasispecies is composed of major viral 
variants represented by the large dark blue virions and minor viral variants represented by the smaller 
green, red, yellow and orange virions. During transmission, there is a narrowing of the genetic 
bottleneck at the point of transmission resulting in the transmission of a minor viral variant (yellow). 
The minor variant (yellow) becomes known as the transmitted/founder virus that establishes infection 
in the newly infected individual.  
 
The bottleneck theory states that a chronically infected and transmitting partner has a diverse viral 
quasispecies consisting of a major viral variant and multiple minor variants (Braibant and Barin, 2013). 
However, at the point of transmission, there is a sharp narrowing of the viral quasispecies towards 
selection for a single viral variant that will be transmitted to the recipient host (Figure 7) (Kariuki et 
al., 2017). Following transmission, the T/F virus remains homogenous in the newly infected recipient 
mainly during Fiebig stage I and Fiebig stage II (the Fiebig classification system is used to identify the 
stages of HIV-1 infection. The Fiebig stage I characterize the period during which HIV-1 RNA becomes 
detectable while Fiebig stage II characterizes the detection of the HIV-1 p24 antigen.  This will be 
discussed in detail in the subsequent paragraphs.) while continuing to replicate at an exponential rate. 
The re-emergence of the viral quasispecies occurs during replication and is chiefly found in the chronic 
phase of infection (Keele et al., 2008).  
 
It remains unclear whether HIV-1 transmission is chiefly a stochastic event or a selective event. 
However, in the experimental design of our study, the HIV-1 LTR element sequences were analysed 
using the plasma samples from the recipients of the HIV-1 infection. Therefore, we did not examine the 
HIV-1 LTR element sequences from other bodily fluids such as genital fluids neither did we examine 
the HIV-1 LTR sequences in both the transmission donor and recipient. Thus, this study was unable to 
provide a distinction of a stochastic event from a rare variant or dominant variant. Therefore, the 
discussion presented here is to briefly understand the events surrounding HIV-1 transmission.  
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Previously, it was suggested that HIV-1 transmission may be a stochastic event in which each viral 
variant present in the quasispecies has an equal probability of transmission (Kariuki et al., 2017). 
Although some stages of transmission may be as a result of stochasticity, recently it has been suggested 
that a selection bias may exist at transmission (Song et al., 2016). Studies in favour of selection bias 
undertake that specific genotypic and phenotypic characteristics may confer increased transmissibility 
(Joseph et al., 2015).  
 
Interestingly, a previous study showed that T/F virus is not the most dominant variant present in the 
plasma or genital tract of the transmitting donor, suggesting that transmission could not be completely 
stochastic (Deymier et al., 2015). Other studies demonstrated that the T/F viruses exhibit consensus like 
sequence particularly when examining the viral gag, pol, nef env genes (env) (Carlson et al., 2014, 
Deymier et al., 2015). While selection bias of the env has been well described, selection bias has also 
been demonstrated outside of the env (Deymier et al., 2015). Therefore, the T/F virus that exhibits a 
greater degree of genetic similarity to the consensus sequence is preferentially selected for at 
transmission.  
 
2.8    The Course of HIV Infection 
 
A typical HIV-1 infection is characterized by three different phases including the acute phase of 
infection, the chronic phase of infection and the final end-stage AIDS phase (Cohen et al., 2016). The 
three phases of infection remain well identifiable (Cohen et al., 2016). A detailed discussion on the 
latter 2 phases of infection are beyond the scope of this study, therefore a brief definition is given. 
Briefly, the chronic phase of infection is defined by the detection of HIV specific antibodies, which 
usually develops after 28 days of infection. This phase of infection is highly variable between patients 
and may persist for 7 to 10 years (Hernandez-Vargas and Middleton, 2013). The chronic stage is 
followed by the end-stage AIDS phase. The end-stage AIDS phase is defined by a CD4+ T-cell count 
that is below 200 cells/mm3 and can be complicated by opportunistic infections thus increasing the risk 
of mortality (Hernandez-Vargas and Middleton, 2013, Rutstein et al., 2017) 
 
 2.9.  Acute Infection 
 
The course of a HIV-1 infection starts with an acute phase of infection, defined as the detection of HIV-
1 RNA and p24 antigens in patient blood prior to the detection of HIV-1 specific antibodies in the blood 
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(Cohen et al., 2016). The acute phase of infection is categorized into 6 different stages known as Fiebig 
stages (Fiebig et al., 2003). The Fiebig stage I is characterized by the detection of only HIV-1 RNA in 
the patients’ blood with Fiebig stage II occurring approximately 7 days thereafter and is defined by the 
detection of HIV-1 RNA and the p24 antigen in the patients’ blood. The Fiebig stage III corresponds to 
a period of 5 days after a positive p24 antigen result and is defined by the detection of HIV-1 
immunoglobulin M (IgM) antibodies by enzyme immunoassays. Fiebig stage IV occurs approximately 
3 days after positive enzyme immunoassay and defined by indeterminate Western blot test and Fiebig 
stage V, which occurs 7 days after Fiebig stage IV or approximately 1 month after infection and is 
defined by clearly positive Western blot test.  
 
The HIV-1 acute infection cohort provides several key characteristics that can be exploited by studies 
aimed at therapeutic interventions. Investigations based on acutely infected individuals could generate 
data that can develop our understanding of HIV-1 transmission pathways further. And, consequentially, 
therapeutic intervention at the acute infection phase could possibly reduce viral load and the size of 
latent reservoir which is a barrier to HIV-1 cure development (Cohen et al., 2010). However, it is well 
established that HIV-1 latency develops early in acute infection and latent reservoirs persists for the 
lifetime of the infected individual. While emphasis has been placed on the acute phase of infection for 
therapeutic interventions, the acute phase of infection has not been fully explored for effective HIV-1 
cure strategies. Although the molecular mechanisms of HIV-1 latency development have not yet been 
fully elucidated, there are a few mechanisms that have been put forward to explain the maintenance of 
HIV-1 latency. Here, we discuss four mechanisms of viral latency that include chromatin configuration, 
nucleosome positioning, DNA methylation and transcriptional interference.  
 
2.9.1   Chromatin Configuration and Epigenetic Modifications 
 
Gene expression of the host and integrated provirus is controlled by the chromatin configuration in a 
dynamic process that alters the configuration of the chromatin to either permit or inhibit host gene 
expression. The nucleosomes are both functional and structural units of chromatins and consists of four 
pairs of core histones that includes H2A, H2B, H3 and H4 (Luger et al., 1997). Importantly, when these 
histones are configured around the integrated proviral core promoter that undergo epigenetic 
modifications that either promote transcription or promote viral silencing. 
 
In addition, in the compact configuration, the tightly bound nucleosomes contain the viral genome in a 
heterochromatin state (Jordan et al., 2003). The heterochromatin configuration limits the accessibility 
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of the viral promoter to the host cellular transcription factors thus repressing viral gene transcription 
(Tripathy et al., 2011; Tamaru 2010). In contrast, in the relaxed configuration, the viral genome is in a 
euchromatin states (Tripathy et al., 2011; Tamaru 2010). This allows for the cellular host transcription 
factors to access the viral promoter and initiate viral gene transcription.  These chromatin configuration 
changes are a result of histone epigenetic modifications.  
 
2.9.2. Histone modifications: Acetylation and Deacetylation 
 
The amino terminal of each histone protrudes to the exterior of the nucleosome thus making itself 
susceptible to epigenetic modifications. Histone modifications are inclusive of sumoylation, ADP 
ribosylation ubiquitination, phosphorylation, methylation and acetylation and are reversible 
modifications (Cain et al., 2011, Lim et al., 2009, Wang et al., 2008). However, for the purpose of this 
dissertation, we will focus on two major histone modifications that is, histone methylation and histone 
acetylation.  
 
The proviral DNA contains two nucleosomes of importance, nucleosome-0 (nuc-0) and nucleosome-1 
(nuc-1) (Rafati et al., 2011, Verdin et al., 1993). Importantly, nuc-1 overlaps with the promoter region 
of the LTR thereby restricting the activity of the transcription initiator site as well as restricting the  
ability of cellular TFs such as LBP-1, AP1 and NFAT to bind to the 5-LTR (Van Lint et al., 1997, Yoon 
et al., 1994). Histone acetylation and methylation play a significant role in either remodelling nuc-1 to 
activate transcription or maintaining the repressive effect of nuc-1, respectively. Histone 
acetyltransferases (HATs) are enzymes that promote acetylation of the amino terminals of the є-amino 
on the lysine residues of H3 and H4 tails. This acetylation promotes remodelling of the nuc-1 to produce 
a euchromatin configuration that promotes viral gene transcription. In contrast Histone Deacetylases 
(HDACs) promote deacetylation of the lysine residue and restore the nuc-1 configuration thereby 
promoting a heterochromatin configuration that represses viral transcription (Archin et al., 2014, Archin 
et al., 2009, Shirakawa et al., 2013). Although there are four classes of HDACs, HDAC1 is the most 
dominant and is recruited to the HIV-1 LTR by TFs such as the NF-кB p50 homodimer.  
 
The HDAC inhibitors, as the name suggest, promotes inhibition of HDACs thus promoting active gene 
transcription. These inhibitors such as suberoylanilide hydroxyamic acid (SAHA) presented as an 
attractive mechanism for HIV-1 latency reversal because they were active in multiple cell types and did 
not elicit global T-cell activation (Archin et al., 2009). Unfortunately, these inhibitors may be able to 
induce the transcription of cancer genes.  
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The second mechanism of histone modification includes histone methylation. The methylation of the 
lysine residues of histone tails is mediated by the histone lysine methyltransferases (HKMTs) that 
catalyse the addition of methyl groups to the amino terminal lysine residue. The histone methylation is 
associated with changes in the steric and hydrophobic characteristics of the histones that may either 
promote or repress viral gene transcription. The methylation of H3K4 induces a state of euchromatin 
and active transcription while methylation of H3K9, H3K27 and H4K20 induces a state of 
heterochromatin and repressed transcription (du Chéné et al., 2007, Friedman et al., 2011, Kim et al., 
2011, Mateescu et al., 2008).  
 
2.9.3.    DNA Methylation 
  
The integrated proviral DNA contain two CpG islands located on the 5’- and 3’- end of the HIV-1 
transcription start site. The DNA methyltransferases (DMTs) catalyse the addition of 5’-methyl groups 
to the CpG dinucleotides. The methylation of the CpG islands is associated with transcriptional 
silencing and a heterochromatin configuration (Blazkova et al., 2009). During HIV-1 latency the CpG 
islands are hypermethylated and are rather responsible for maintaining viral latency rather than inducing 
viral latency. Hypermethylated CpG islands directly block the ability of transcription factors to bind to 
the viral promoter or they may indirectly block transaction factor binding by the addition of methyl-
CpG-binding proteins (MBDs) (Bednarik et al., 1991).  The MBDs further recruit HMTs and HDACs 
that promote a repressed heterochromatin configuration thus maintaining a state of viral latency 
(Blazkova et al., 2009). In addition to this, one of the hypermethylated CpG islands recruit the MBD2 
and HDAC2 that enforce a transcriptionally repressive state (Kauder et al., 2009).  
 
2.9.4.      Transcriptional Interference 
 
The mechanism of transcriptional interference is dependent on the orientation of the viral promoter 
integration site. Transcriptional interference can mediate suppression of viral transcription through 
promoter exclusion or collision. When the viral promoter is integrated into the host genome in the same 
orientation as a second promoter, the upstream RNA pol II transcription complex causes promoter 
occlusion by read through transcription that dislodges transcription factors bound to the viral promoter 
and promotes a state of viral transcription repression (Greger et al., 1998, Lenasi et al., 2008). In 
addition, this read through can also block the viral promoter from accessing the available cellular 
transcription factors. In contrast, when the viral promoter is integrated into the host genome in the 
opposite orientation to that of a second promoter, the two active RNA Pol II transcription complexes 
eventually collide and result in the premature termination of transcription elongation (Crampton et al., 
2006, Lewinski et al., 2005). This may supress either one or both promoters resulting in transcriptional 
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silencing. However, although the collision of the transcriptional complexes can occur, another 
possibility exists in which the RNA Pol II complexes may converge and produce double stranded viral 
RNA that may participate in RNA interference to mediate transcriptional silencing.  
 
The evidence put forward by the various studies suggests that the LTR is a prominent region of interest 
which could direct further studies that assists in cure development. Several mechanisms of HIV-1 
latency development have been described, and latency development may be an interplay of several 
mechanisms. However, the HIV-1 LTR plays a central role in HIV-1 latency development and therefore 
studying the HIV- LTR presents an attractive target for future HIV-1 cure strategies. Since many studies 
have characterized HIV-1 subtype C in countries that include Brazil, India and China, South Africa is 
requiring further knowledge about HIV-1 subtype C which presents as the main subtype responsible for 
the pandemic. Thus, the characterization and establishment of the sequence variations exhibited by the 
South African subtype C will contribute to the broader aim of HIV cure developments. 
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CHAPTER 3: METHODOLOGY 
 
3.1.    Study design, Inclusion and Exclusion Criteria 
 
The study population includes participants from two study cohorts namely, the Females Rising through 
Education, Support and Health (FRESH) acute infection and, the HIV Pathogenesis Programme (HPP) 
acute infection. This study strictly included plasma samples that were obtained during the acute phase 
of infection from patients that were antiretroviral naïve.  
 
The FRESH cohort is an ongoing prospective study as previously described by (Dong et al., 2018). This 
cohort was initiated to detect acute HIV infection in young females who were at high risk for HIV 
infection. In doing so, this cohort enables the collection of blood samples prior to HIV infection as well 
as after HIV infection. Thus, contributing to the study of HIV-1 pathogenesis and the behavioural and 
biological risk factors associated with the risk of HIV acquisition. This study recruited young females 
aged between 18-23 years old that were HIV negative but at high risk of HIV acquisition and provided 
written consent for enrolment. The duration of surveillance was set at 48 weeks since 1st May 2015.  
 
The FRESH study consisted of two objectives. The first objective was socioeconomic empowerment 
through the attendance of twice-weekly classes. The second objective was consent to participate in a 
twice-weekly HIV-1 finger prick test to detect acute HIV-1 infection. During the initial 19 months of 
surveillance, participants diagnosed with acute HIV-1 infection did not begin treatment immediately. 
Instead, they were monitored and referred for treatment according to the South African eligibility 
criteria at that time. However, in July 2014, antiretroviral therapy (ART) was administered immediately 
upon detection of acute HIV-1 infection according to the South African Test and Treat strategy.  
 
Initially, 945 participants were enrolled to begin the 48-week surveillance period. Of this, 42 
participants were diagnosed with acute HIV infection and were put on a 156-week monitoring 
programme. Thereafter, of the 42 acutely infected participants, 14 individuals remained treatment naïve 
while 28 individuals received early ART treatment (that is, ART was initiated during the acute stage of 
infection). From the 14 treatment naive participants, 1 individual had withdrawn from the study and 
only 13 participants remained treatment naïve and were in follow up. Of these 13 individuals, 7 patients 
began ART treatment while 6 remained treatment naïve. For this study, 4 treatment naïve samples were 
selected for analyses.  
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In addition, HIV-1 infected plasma samples were obtained from the HIV Pathogenesis Program (HPP) 
acute infection cohort previously described (Gounder et al., 2015b). Initially, a total of 22 acutely 
infected antiretroviral naïve participants were enrolled into the HIV Pathogenesis Programme Acute 
Infection Cohort based in Durban, South Africa. During screening, all participants exhibited detectable 
HIV-1 RNA levels but had not yet seroconverted. Therefore, these participants were described as 
acutely infected according to the CDC’s criteria and definition of HIV-1 acute infection. The date of 
HIV-1 infection was estimated to be approximately 14 days before screening. Participants provided 
written informed consent and blood samples were collected at intervals of enrolment, at 2 weeks, 4 
weeks, 2, 3 and 6 months. Thereafter blood samples were collected every 6 months following infection 
(Gounder et al., 2015a). The viral load and CD4 count was measured at every time visit using the Roche 
Cobas Taqman HIV-1 Test v2.0 (Roche Diagnostics, Branchburg, NJ, USA) and the 4-colour 
MultiTEST/Trucount assay (Becton Dickinson, San Jose, CA, USA), respectively (Gounder et al., 
2015a). To date, 44 acutely infected participants were recruited. Plasma samples (24 samples) obtained 
from two study visits, at or near transmission and at one-year post-infection was made available for this 
study.  
 
The 25 plasma samples (4 FRESH acute plasma samples and 21 HPP acute plasma samples) used in 
this study was selected based on the availability of plasma samples at the HIV Pathogenesis Programme 
(HPP) Laboratory. Furthermore, going forward into to the thesis, the study participants will be referred 
to as acutely infected antiretroviral therapy naïve patients.  Approval for this study was obtained from 
the Biomedical Research and Ethics Committee of the University of Kwa-Zulu Natal (REF: 
BREC/00001051/2020). 
 
3.2      Polymerase Chain Reaction (PCR) Amplification 
 
First round PCR products were used as a template for nested PCR which was carried out using 
Platinum® Taq DNA Polymerase High Fidelity PCR Kit (Invitrogen, Thermofisher Scientific, 
Massachusetts, United States) as per the manufacturers’ instructions. Briefly, the PCR reaction was set 
up by mixing 1X High Fidelity PCR Buffer, 0.1 µM sense primer (T7-U3-M-
F:5’taatacgactcactatagggTTTTTAAA AGAAAAGGGGGGAC-3’_nt 9064 to 9085), 0.1 µM antisense 
primer (3’Sp6 R-M-R: 5’atttaggtgacactatagATTGAGGCTTA AGCAGTG GGTT-3’_nt 9614 to 9593), 
0.2 µM dNTP mix, 2 µM MgSO4, 1 U Taq DNA Polymerase, 2 µL of template DNA (T/F LTR PCR1 
products, which is already available in the laboratory) and this was made to a final PCR reaction volume 
of 50 µL with PCR grade water. The thermocycler conditions for the PCR reaction included an initial 
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denaturation at 94˚C for 15 seconds, 25 cycles of denaturation at 94˚C for 15 seconds, annealing at 55˚C 
for 30 seconds, extension at 68˚C for 60 seconds and a final extension at 68˚C for 5 minutes. 
 
3.3          Agarose Gel Electrophoresis 
 
The PCR products were analysed on a 1% agarose gel to confirm the size and specificity of the amplified 
band. The 1 Kb Plus DNA Ladder (Invitrogen, Thermofisher Scientific, Massachusetts, United States) 
was used as a molecular weight marker and the gel was run at 95v for 1 hour as established in the 
laboratory. 
 
3.4          Gel Extraction 
 
The nested PCR products were gel extracted using the GeneJet Gel Extraction Kit (Thermofisher 
Scientific, K0692) as per manufacturer’s instructions. Briefly, 45 µL of the nested PCR product was 
run on a 1% agarose gel that was not exposed to ultraviolet light prior to extraction to protect the 
integrity of the DNA contained within the gel bands. In preparation for gel extraction, an empty 1.5 mL 
Eppendorf was pre-weighed to establish the weight of the empty Eppendorf. Thereafter, the specific 
PCR bands were extracted using a gel extractor (Merck, Germany, Darmstadt). The gel slice was then 
transferred to the pre-weighed 1.5 mL Eppendorf and thereafter the Eppendorf containing the extracted 
gel slice was weighed again. The weight of the gel slice was then calculated (Weight of the gel slice in 
Eppendorf – Weight of the pre-weighed empty Eppendorf = Weight of the gel slice) to determine the 
volume of binding buffer required in the subsequent step. 
 
Thereafter, Binding buffer was added to each tube containing the gel slice in a 1:1 ratio (Add 100 µL 
of binding buffer per 100 mg of gel slice) and incubated at 50 - 60 °C for 10 minutes in a dry heating 
block. The dissolved gel slice mixture was then briefly vortexed for 10 seconds and transferred to a 
GeneJet column followed by centrifugation at 13 000 rpm for 1 minute. The flow through was then 
discarded and 100 µL of Binding buffer was then added to the columns and centrifuged at 13 000 rpm 
for 1 minute.  Thereafter, the flow through was discarded and 700 µL of Ethanol Wash solution was 
added to each column followed by centrifugation at 13 000 rpm for 1 minute. The flow through was 
once again discarded and the empty column centrifuged for an additional 1 minute to remove the 
residual ethanol from the wash solution. The column was then transferred to the labelled 1.5 mL 
Eppendorf’s and 20 µL of elution buffer was added to the centre of each column. The columns were 
then incubated at room temperature for 2 minutes followed by centrifugation at 13 000 rpm for 1 minute. 
The eluted DNA was stored at -20 ° or used immediately.  
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3.5          Cloning 
 
3.5.1       Restriction digestion and ligation 
 
Briefly, the gel extracted nested PCR product was cloned into the pGL3 Basic vector (Promega, USA, 
Madison) which contains the luciferase reporter gene (Gray et al., 2013). Firstly, the pGL3 Basic vector 
was digested with the two sticky ends restriction enzymes, Kpn1 (New England Biolabs, USA, 
Massachusetts) and HindIII ((New England Biolabs, USA, Massachusetts). The restriction digestion 
reaction was then run on a 1% agarose gel for 1 hour at 95v as established in laboratory protocol. This 
gel was not exposed to ultraviolet light prior to extraction to protect the integrity of the plasmid DNA 
contained within the gel band. In preparation for gel extraction, an empty 1.5 mL Eppendorf was pre-
weighed to establish the weight of the empty Eppendorf. Thereafter, the specific PCR bands were 
extracted using a gel extractor (Merck, Germany, Darmstadt). The gel slice was then transferred to the 
pre-weighed 1.5 mL Eppendorf and thereafter the Eppendorf containing the extracted gel slice was 
weighed again. The weight of the gel slice was then calculated (Weight of the gel slice in Eppendorf – 
Weight of the pre-weighed empty Eppendorf = Weight of the gel slice) to determine the volume of 
binding buffer required in the subsequent step. The gel purification of the linearized pGL3 was 
performed using the GeneJet Gel extraction kit (Thermofisher Scientific, K0692) as per the 
manufacturer’s instruction as we had briefly highlighted above.  
 
The same sticky end restriction enzymes (Kpn1and HindIII) were used to digest the nested PCR 
product, patient derived HIV-1 LTR U3R region to create the same sticky ends. The digested patient 
derived U3R region was cloned into the linearized pGL3 Basic vector followed by the ligation using 1 
U of T4 DNA ligase (New England Biolabs, USA, Massachusetts) as per manufacturer’s instructions. 
Briefly, a recombinant pGL3 Basic vector was created by preparing a 20µL of the ligation reaction 
mixture containing 37.5 ng of insert DNA, 50 ng of plasmid DNA, 1X T4 DNA ligase buffer, 1 U of 
T4 DNA ligase with the reaction volume being made up to 20 µL using nuclease free water. The ligation 
reaction was then incubated for 10 minutes at room temperature and thereafter returned to ice for the 
subsequent transformation reaction.  
 
3.5.2      Transformation 
 
Following ligation, transformation of the recombinant pGL3 plasmid into JM109 competent E. coli 
cells (Promega, USA, Madison) was performed as per manufacturer’s instructions. JM109 competent 
E.coli cells were thawed on ice for no more than one minute. Following thawing, 10 µL of the 
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recombinant DNA molecules was added to 50 µL of pre-chilled JM109 competent E. coli cells 
immediately followed by incubation on ice for 30 minutes. The competent E. coli cells and recombinant 
DNA was heat shocked in a water bath at 42˚C for 20 seconds and the Eppendorf tube was subsequently 
chilled on ice for 2 minutes. Thereafter, 450 µL of the SOC medium was added to the heat shocked 
cells followed by incubation at 37 °C while shaking at 250 rpm for one hour. Thereafter, 100 µL of the 
transformation reaction was added to the ampicillin containing LB agar plate and spread over the surface 
of the plates. The plates were incubated at 37˚C for 16-20 hours.  
 
 
3.5.3      Plasmid Miniprep 
 
Following the transformation reaction, the agar plates were checked after a 16- hour overnight 
incubation at 37 ˚C to confirm bacterial growth. The inoculated agar plates contained numerous single 
colonies upon successful transformation. Thereafter, ampicillin containing Lysogeny Broth (LB) Broth 
was prepared by aliquoting 3.0 mL of broth and 100 µg/ mL of ampicillin in a tube. Prior to inoculation 
of the LB broth with a bacterial colony, a master plate was prepared to store the bacterial colonies used 
for inoculation. A single bacterial colony was picked up from the lawn of bacteria and this was then 
used to inoculate a labelled master plate. Subsequently, the same bacterial colony was inoculated into 
a single tube of ampicillin containing LB broth. The inoculated tubes were then placed in a horizontal 
shaker with shaking at 230 rpm at 37˚C overnight.  
 
Following bacterial growth in the LB broth, the LB broth had then changed to a cloudy appearance 
confirming bacterial growth in the LB broth. The plasmid DNA was then isolated from the bacterial 
colonies using the GeneJet Plasmid Mini Prep Kit (Invitrogen, Carlsbad, CA) as per the manufacturers’ 
instructions. Briefly, the bacterial cells from the LB broth were harvested via centrifugation (Heraeus 
Biofuge Fresco, England, United Kingdom) at 8000 rpm for 2 minutes to form a pellet. The bacterial 
pellet was then resuspended in 250 µL of Resuspension Solution while taking caution to ensure a clump 
free suspension. Lyses of the bacterial cells was achieved by the addition of 250 µL of Lysis Solution 
followed by the addition of 350 µL of Neutralization Solution ensuring to mix thoroughly. The removal 
of the cell debris and chromosomal DNA was achieved by centrifugation (Heraeus Biofuge Fresco, 
England, United Kingdom) for 5 minutes at 13000 rpm 
 
The supernatant consisting of the plasmid DNA was transferred to a GeneJet spin column followed by 
centrifugation (Heraeus Biofuge Fresco, England, United Kingdom) at 13000 rpm for 1 minute. 
Subsequently, the flow through was discarded and 500 µL of Wash Solution was added to the GeneJet 
 
35 
 
spin column followed by centrifugation (Heraeus Biofuge Fresco, England, United Kingdom) for 30-
60 seconds at 13000 rpm. The wash procedure was repeated with an additional centrifugation (Heraeus 
Biofuge Fresco, England, United Kingdom) for 1 minute at 13000 rpm to ensure removal of the ethanol 
wash solution. Thereafter, the GeneJet spin column was transferred to a clean 1.5 mL Eppendorf with 
subsequent addition of 30 µL of pre-warmed Elution Buffer to the spin column. Following incubation 
for 2 minutes at room temperature the plasmid DNA was centrifuged (Heraeus Biofuge Fresco, 
England, United Kingdom) for 2 minutes at 13000 rpm. The DNA concentration of the prepared plasmid 
DNA was quantified using Nanodrop™. The plasmid DNA was then used immediately or stored at -
20˚C.  
 
3.6      Sequencing 
 
The plasmid miniprep recombinant clones was then sequenced directly using the Big Dye Terminator 
v3.1 Sequencing Kit (Thermofisher Scientific, Massachusetts, United States). A sequencing master mix 
was prepared by the combination of 3.4 µL of PCR grade water, 2 µL sequencing buffer, 2 µL of either 
the 0.4 µM sense  primer (T7-U3-M-F:5’taatacgactcactatagggTTTTTAAA AGAAAAGGGGGGAC-
3’_nt 9064 to 9085) or the 0.4 µM antisense  primer (3’Sp6 RMR: 5’atttaggtgacactatagATTGA 
GGCTTAAGCAGTG GGTT-3’_nt 9614 to 9593), 0.4 µL of BigDye v3.1 and 1 µL of DNA template 
(20ng/µL). Cycle sequencing reaction was performed separately for each primer. The reaction was 
centrifuged (Eppendorf 5810R) and placed in a thermocycler with the following thermocycling 
conditions: pre-denaturation at 96˚C for 1 minute, 25 cycles of denaturation at 96˚C for 10 seconds, 
annealing at 50˚C for 5 seconds, extension at 50˚C for 4 seconds and held at 4˚C. The sequencing plates 
were stored at 4˚C and protected from exposure to light.  
 
Subsequently, after the sequencing reaction, 1 µL of 125mM EDTA was added to each well and 
mixed thoroughly. Thereafter a mixture of 1 µL of 3M NaOAc (pH 5.2) and 25 µL of 100% ice cold 
ethanol was added to each well. The plate was then vortexed thoroughly and centrifuged (Eppendorf 
5810R) for 20 minutes at 3000 rpm. The plate was subsequently inverted onto a paper towel and 
centrifuged (Eppendorf 5810R) again for 1 minute at 150 x g. Following that, 35 µL of 70% ethanol 
was added to each well and centrifuged (Eppendorf 5810R) for 5 minutes at 3000 rpm. Subsequently 
the plate was inverted onto a paper towel and centrifuged for 1 minute at 150 rpm. The samples were 
then dried in a thermocycler for 5 minutes at 50˚C. The plate was then sealed using adhesive foil and 
stored at -20˚C in preparation for sequencing 
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3.7        Sequence Analysis 
 
Sequence analysis was performed using Sequencher 5.1. The sequences were assembled into contigs 
and edited manually using Sequencher 5.1 (Gene Codes, Ann Arbor, Michigan, USA).Thereafter, a 
multiple sequence alignment was performed using Jalview v2.10.5 (Waterhouse et al., 2009). The 
sequences were then examined on Bioedit Sequence Alignment Editor v7.2.5 (Hall, 1999) to detect 
mutations within the U3R region of the patient LTR elements. Similarity between PCR-derived 
sequences and clonal sequences were determined by the construction of a phylogenetic tree using the 
online tool Phyml (https://www.hiv.lanl.gov/content/sequence/PHYML/interface.html). The 
phylogenetic tree was then viewed and edited using FigTree Tree Figure Drawing Tool v1.4.3.  
 
3.8        Transfection into Jurkat Cells 
 
Briefly, Jurkat cells were thawed in a 37˚C water bath for no longer than 3 minutes. The cells were 
grown as suspension cells in RPMI 1640 medium supplemented with 10% Fetal bovine serum (FBS), 
penstrep and L-Glutamine (R10 medium). The cells were grown to a viability of 95% or higher in 
preparation for transfection. Jurkat cells were transiently transfected with Lipofectamine 2000 
transfection reagent (catalog no.11668-019, Invitrogen) as previously described by Bachu et al., (2012).  
 
Briefly, Jurkat cells were seeded into 24-well tissue culture plates at a density of 5 x105 cells/well in 
400 µL of antibiotic-free RPMI 1640 medium supplemented with 10% FBS. Thereafter, 300 ng of the 
recombinant LTR- containing pGL3 plasmid was prepared in 50 µL of serum-free RPMI medium. For 
the LTR-Tat (WT subtype C) or LTR-Tat (autologous) co-transfection assay, a plasmid pool of 300 ng 
of the recombinant LTR-containing pGL3 plasmid and 100 ng of WT subtype C Tat expression vector 
or autologous tat expression vector was prepared in 50 µL of serum-free RPMI medium.  A total of 1 
µL of Lipofectamine was mixed with 49 µL of serum-free RPMI medium to prepare the lipid 
transfection reagent. Then, the 50 µL lipofectamine-RPMI mixture was mixed with 50 µL of the 
recombinant pGL3 plasmid DNA. The plasmid-lipid mixture was then incubated for 20 minutes at room 
temperature and subsequently added to the appropriate wells. Twelve hours following the transfection, 
the cells were washed to remove the lipid complexes and resuspended in 500 µL of R10 medium. The 
transfection reaction was then incubated for 24 hours followed by a luciferase assay.  
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3.9. Cell Activation Assay 
 
Jurkat cells were transiently transfected or co-transfected with the autologous Tat expression vector as 
described in section (3.8). Twelve hours following the transfection, the cells were washed to remove 
the lipid complexes and resuspended in 500 µL of R10 medium. The transient transfection was then 
stimulated with one of the following cell activators: TNF-α (20 ng/mL), PMA (20 ng/mL), SAHA (20 
ng/mL) or Prostratin (20 ng/mL) as previously described (Bachu et al., 2012). The stimulated cells were 
then incubated for 24 hours after which the luciferase activity was measured.  
 
3.10       Luciferase Assay  
 
Bright-Glo (Promega, Madison, United States) was thawed at an ambient temperature water bath away 
from light. Thereafter 350 µL of the culture medium was aspirated from the 500 µL transfection reaction 
such that 150 µL of culture medium remained in each well. Subsequently, 100µL of Bright-Glo was 
added to each well followed by incubation for 2 minutes with the plate being shielded from light. The 
cells in each well were then mixed by two pipette strokes to lyse open the cells followed by the transfer 
of the 150µL of lysed cells into the wells of a black round bottom 96 well plate. The expression of the 
Luciferase was read immediately using the Victor Nivo Multimode plate recorder (PerkinElmer, 
Massachusetts, USA).  
 
 
3.11       Statistical Analyses 
 
Statistical analysis was performed using Graphpad Prism 5 software for Windows, GraphPad 
Software, San Diego California USA, (www.graphpad.com). The statistical significance for the 
transfection assay and association of viral load with LTR mutants was determined using a paired T-
test. Linear regression analyses were used to determine the statistical significance and correlation 
coefficient of the correlation between transcription activity and markers of disease progression. The p 
value <0.05 was considered statistical significance 
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CHAPTER 4: RESULTS 
 
 
4.1. Demographic Characteristics of 25 Patients from HPP and FRESH Cohort  
 
The U3R region of 25 patient LTR elements was amplified from viral RNA obtained from patients in 
the HPP and FRESH acute infection cohorts. The amplification of the U3R region was performed from 
viral RNA obtained at two study time points per patient. Due to sample availability, the first time point 
was obtained close to transmission, that is, at a median of four weeks post-infection (denoted as B2) 
[patient plasma samples were Western blot negative but HIV-1 RNA positive] and the second time 
point was at one-year post infection (denoted as B7). The selection of these two time points allowed us 
to examine the diversification of the LTR elements by one-year post-infection. In addition, phylogenetic 
analysis was used to determine interpatient LTR genetic variability.   
 
 
4.2. LTR Diversification of the T/F Virus During Acute Infection 
 
To examine the LTR diversity of the 25 patients, the U3R region of LTR elements were amplified at 
the aforementioned timepoints and then directly sequenced from the PCR products to generate bulk 
sequences. A phylogenetic tree was then constructed to determine whether there is interpatient LTR 
genetic variability as well to determine the diversification of the T/F virus patients LTR by one-year 
post infection (Figure 8). The 25 patients were infected with HIV-1 subtype C viruses and the 
phylogenetic tree was rerooted against the Indian subtype C reference sequence (EF17 8613.1). 
Phylogenetic analysis demonstrates that each patient LTR sequences formed independent clusters and 
there was no indication of any interpatient relatedness. This further demonstrates that each patients’ 
infection is as a result of an unrelated T/F viral variant and confirms interpatient LTR genetic variability.   
Phylogenetic branching showed that the LTR is subject to evolution within a patient within one-year of 
infection. This was shown in 14 out of 25 patients (56%), while 11 out of 25 (44%) patients maintained 
homogeneous LTR sequences within one-year post-infection. The analysis of env sequence data would 
be valuable to better understand the transmission pairs. However, env sequence analysis was beyond 
the scope of the study presented in this dissertation. The env sequence data of the transmission pairs 
will be analysed and included for the publication purposes..  
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Figure 8. Phylogenetic analysis demonstrates interpatient LTR sequence variation.  Phylogenetic 
analysis was performed using 25 patient derived LTR elements from the HPP and FRESH cohort. The 
tree was constructed using the online tool Phmyl (http://www.hivlanl.gov) and rerooted on the Indian 
subtype C reference sequence (EF178613.1) using FigTree Tree Figure Drawing Tool v1.4.3. The viral 
sequences obtained near transmission are denoted as B2 while the viral sequences obtained at one-year 
post infection are denoted as B7. Each patients LTR element clusters independently together thus 
demonstrating that the LTR element is variable between patients. Phylogenetic branching demonstrates 
that the LTR may evolve within one-year of infection within a patient. 
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4.3. The South African Subtype C U3R region is Variable at Transmission 
 
Next we hypothesized that there may be genetic variation within the transcription factor binding sites 
of the U3R region as previously reported for HIV-1C circulating in India (Bachu et al., 2012). To this 
effect, the U3R region sequences aligned with the Indian subtype C reference sequence (EF178613.1) 
using Jalview v2.10.5 (Waterhouse et al., 2009) since this reference sequence contained more than 3 
NF-кB binding sites. Interestingly, the transcription factor binding sites (TFBS) USF, RBE III site, the 
Sp1 I, Sp1 II and Sp1 III sites, the TATA Box, E- Box, 2 conserved NF-kB binding sites (NF-kB I and 
NF-kB II), an additional 3rd NF-kB binding site specific to subtype C and TAR region clearly aligned 
with the TFBS in the reference sequence. Specifically, the USF region within the modulatory domain 
and the TAR loop region within the R region demonstrated interpatient LTR variability. However, the 
core enhancer and promoter region were relatively well conserved with the exception of the Sp1 III 
binding site that exhibited a greater degree of interpatient variability within the core promoter region.  
 
The USF transcription factor binds to the USF binding site. The USF transcription factor binds the E-
box sequence that overlaps the -170 C/EBP region within the modulatory domain (di Fagagna et al., 
1995, Schwartz et al., 2000, Tesmer et al., 1993). This interaction was reported to activate transcription 
in T-cells (Naghavi et al., 2001). Interestingly, our results demonstrated that the USF region in this 
cohort is not conserved. This region primarily exhibited variation at position 4 of the USF binding site 
sequence (CACCTGGCCC  CACA/TTGGCCC). This nucleotide change was observed in 13 out of 
25 patients (52%). The C  A nucleotide change at position 4  is consistent with a previous study 
however, this is not a subtype C specific mutation as it was also shown to occur in subtypes D, E and F  
(Jeeninga et al., 2000) (Figure 9).  
 
The RBE III site, located in the modulatory region, is a binding site for the cellular factor RBF-2 (Ras 
Response Element-2). Overall, all patient LTRs’ contained the complete canonical sequence 
GACTGCTGA for the RBE III binding site (Figure 9). The RBE III site (GACTGCTGA) is well 
conserved in subtype C as previously reported. However, our results demonstrated conservation of the 
RBE III site in 22 out of the 25 (88%) patient RBE III binding sites while the RBE III site variability 
was observed in 3 out of the 25 (12%) patient LTR element (patient AS02-802, AS02-945 and AS02-
182). In patient 802, the C nucleotide at position 6 was substituted for an A nucleotide (GACTGCTGA 
 GACTGATGA), however, in patient 945 and 182 we observed a CTGAGA and CTGCTGACTTTG 
sequence insertion within the RBE III site, respectively.
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Figure 9. Multiple sequence alignment demonstrating PCR-derived sequence of the modulatory, core enhancer and core promoter region within the 
patient LTR elements. The LTR element sequences were aligned against the Indian subtype C reference sequence, EF178613.1. The dots represent nucleotide 
bases that are identical to the reference sequence while the dashes indicate deletions. The various coloured labelled blocks represent the transcription factor 
binding sites within the enhancer and promoter region. From left to right: the USF binding site is represented by blue shading,  RBE III site is represented by 
purple shading, the 4th NF-кB (designated F-NF-кB) is represented by light blue shading while the two canonical NF-кB binding sites (designated NF-кB I and 
II) are shown by green shading. The 3rd-NF-кB site (designated C-NF-кB) is shown by red shading, the three Sp1 I, II and III binding site are represented by 
grey, yellow and orange shading respectively. The Tata box and E-box are represented by brown and dark pink shading respectively, while the TAR loop region 
is shaded with light pink. Nucleotide sequence analysis confirms interpatient variability within the TFBS. Overall, the T/F virus canonical sequences were 
relatively conserved within the core enhancer, nonetheless variation was observed within the RBE III site, Sp1 III binding site and TATA Box. Overall, the T/F 
virus was conserved within a patient at transmission and one-year post infection. 
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Upstream from the RBE III site is the enhancer region which exhibits variation due to differences in 
NF-кB binding site copy number. Consistent with the previous study (Baar et al., 2000), our data 
demonstrate the two canonical NF-kB binding sites were conserved among all 25-patient derived LTR 
elements. The NF-кB binding site copy number is subtype dependent. Most HIV-1 subtypes exhibit 
two NF-кB binding sites with subtype C exhibiting at least 3 NF-кB binding sites (Baar et al., 2000, 
Bachu et al., 2012, Boullosa et al., 2014, Hunt and Tiemessen, 2000, Hunt et al., 2001, Scriba et al., 
2002). The identification of the 3rd NF-kB (C-NF-кB) binding site confirms that South African cohorts 
used in this study are infected with HIV-1 subtype C. The 3rd- NF-кB binding site was observed in 
100% of patient isolates with 4 out of 25 (16%) patients having an NF-кB like site at the third NF-кB 
position. NF-кB-like binding sites are those NF-кB binding sites that have single nucleotide changes 
and thus resemble NF-кB binding sites (Figure 9). 
 
Interestingly, a unique characteristic of the subtype C viruses is the occurrence of a fourth NF-кB 
binding site (Bachu et al., 2012). Consistent, with studies by Hunt et al., (2001), Scriba et al., (2000), 
Bachu et al., (2012) and Boullosa et al., (2014), our data demonstrates the occurrence of the 4th-NF-кB 
in South African subtype C viruses (Figure 9). However, while viruses containing the 4th NF-кB 
binding site show an increased expansion in India, our data demonstrates that viruses containing the 4th 
NF-кB binding site are found at a low frequency in South Africa. Specifically, the 4th NF-кB binding 
site was observed in 2 out of 25 (8%) patient derived LTR elements and this was observed for both the 
LTR elements obtained at or near transmission and as well as at one-year post infection (patients AS21-
187 and AS02-1034). This finding is consistent with previously reported findings from subtype C 
viruses circulating in South Africa (Hunt et al., 2001, Scriba et al., 2000). 
 
Consistent with the published data (Baar et al., 2000, Jeeninga et al., 2000), our data demonstrate that 
the core promoter domain consists of 3 tandem Sp1 binding sites the TATA box and E-Box. The Sp1 
III binding site exhibited the most variability in comparison to the Sp1 I and Sp1 II binding sites 
consistent with  previous studies (Bachu et al., 2012, Boullosa et al., 2014, McAllister et al., 2000, 
Nonnemacher et al., 2004). The subtype C consensus Sp1 III sequence was only observed in 1 out of 
25 (4%) patient derived LTR elements (patient AS02-341). However, in the remaining 24 out of 25 
(96%) patients, two dominant nucleotide changes existed among this set of patient sequences. The 
consensus nucleotide (G) at position two was substituted for an A nucleotide (GGGGAGTGG  
GAGGAGTGG) in 13 out of 25 (52%) patients while at position 5, the consensus nucleotide (A) was 
substituted for a T nucleotide (GGGGAGTGG  GGGGTGTGG) in 15 out of 25 (48%) patients  
(Figure 8). These G2A and A5T mutations existed as either independent single nucleotide mutations 
in 12 out of 25 (60%) patients or as co-mutations in 11 out of 25 (44%) patients. The Sp1 I and Sp1 II 
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binding sites were relatively conserved to the consensus sequence, exhibiting a single nucleotide change 
at position 9 and 10 and at position 10, respectively.  
 
Downstream of the Sp1 binding sites, the TATA box was relatively conserved in 24 out of 25 (96%) 
patient samples. The TATA Box is found upstream of the transcription start site and has a conserved 
nucleotide sequence in all HIV-1 subtypes with the exception of subtype E (Montano et al., 1998, 
Montano et al., 1997). Particularly in subtype E viruses, the TATA box sequence is polymorphic having 
a single nucleotide change at position three (TATAA  TAAAA). Interestingly, our data demonstrate 
that one patient (187) was infected with a subtype C strain harbouring this TATA box mutation 
(TATAA  TAAAA). Therefore, the TATA box mutant was rare (4%) among the viruses obtained 
from this set of PLHIV in South Africa (Figure 9).  
 
3.4. Phylogenetic Analysis Confirms Similarity between Bulk Sequence and pGL3-LTR                 
Recombinant Clones 
 
Here, we hypothesized the subtype C T/F viruses LTR derived clones will have the same sequences as 
the bulk sequences since T/F viruses are homogenous. To this effect a total of 14 representative patient 
derived LTR element sequences were selected to assess their transcription activity. The 14 
representative patient samples selected for the downstream assays were the preliminary sequence data 
for this study and had demonstrated sequence variations of interest which include the 4th-NF-кB binding 
site, the Sp1 III: G2A and Sp1 III:A5T mutant, the TATA box: T3A mutant.  
 
Specifically, we selected sequences exhibiting variation within the RBE III site, NF-кB binding site and 
copy number, Sp1 III binding site, TATA Box, E-box and this was in addition to other mutations. These 
14 LTR elements were amplified using nested PCR, cloned into the pGL3 Basic vector ((Promega, 
USA, Madison) and transformed into E. coli competent cells (Promega, USA, Madison). A single 
random colony was selected per patient derived LTR pGL3 recombinant clone and sequenced. The 
patient derived LTR sequences spanning the core enhancer and core promoter region were analysed 
because variation within this region has been reported to dysregulate viral gene transcription. Therefore, 
this phylogenetic analysis was restricted to the core enhancer and promoter region only. 
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Figure 10. Phylogenetic tree demonstrating similarity between the bulk sequence and the clonal 
sequences. Phylogenetic analysis was completed using the 14 patient derived LTR elements from the 
HPP cohort. The tree was re-rooted on the Indian subtype C reference sequence (EF178613.1) using 
FigTree Tree Figure Drawing Tool v1.4.3. Both bulk and one clonal sequence was generated for each 
of the 14 patients and the bulk sequence and clonal sequence clustered together per patient. The patient 
identities are denoted with B2 indicative of viral sequences close to the transmission event.  
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A single randomly picked and sequenced clone (referred to as clonal sequence) together with the 
respective patient bulk sequence formed independent clusters. The monophyletic structure of each 
cluster indicates that there was no contamination or intermingling of the sequences between patients. 
Furthermore, the branching structure of the clonal and bulk sequence indicates homogeneity of the T/F 
viruses within a patient (Figure 10).  Therefore, phylogenetic analysis confirms that the clonal sequence 
contains an identical nucleotide sequence to that of bulk sequence near transmission. 
 
 
4.5. Nucleotide Sequences confirms the Bulk and Clonal Sequences are Identical within the 
Core Enhancer and Core Promoter Region  
 
Although the phylogenetic tree confirmed that the bulk and representative clone is identical, we 
performed a nucleotide alignment of the bulk and clonal sequence to examine the modulatory region, 
core enhancer and core promoter region at the nucleotide level. The bulk sequence and clonal sequence 
showed 100% alignment thus demonstrating that each patients’ representative clone accurately 
represented the modulatory region, core enhancer and core promoter of the PCR-derived sequence 
(Figure 11). This single representative clone was selected for the downstream functional assays.  
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Figure 11 Multiple sequence alignment demonstrating both clonal and PCR-derived sequence of enhancer and promoter region within the patient LTR 
elements. The LTR element sequences were aligned against the Indian subtype C reference sequence, EF178613.1. The dots represent nucleotide bases that are 
identical to the reference sequence while the dashes indicate deletions. The various coloured labelled blocks represent the transcription factor binding sites 
within the enhancer and promoter region. From left to right: the RBE III site is represented by purple shading, the 4th NF-кB (designated F-NF-кB) is represented 
by blue shading while the two canonical NF-кB binding sites (designated NF-кB I and II) are shown by green shading. The 3rd-NF-кB site (designated C-NF-
кB is shown by red shading, the three Sp1 I, II and III binding site are represented by grey, yellow and orange shading respectively, while the Tata box and E-
box are represented by brown and pink shading respectively. Shown above are the PCR-derived sequence along with the respective clonal sequence for 7 
patients are representative of the 14 patients that were cloned. The nucleotide alignment demonstrates that the clonal sequence is identical to the PCR-derived 
sequence.
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4.6. Differential Transcriptional Activity of HIV-1 Subtype C T/F viruses LTR variants 
Between Patients 
 
 Next we hypothesized that sequence variation within the transcription factor binding sites (TFBS) may 
alter the ability of the LTR to bind their respective transcription factors. Especially, the Sp1 III binding 
site where we observed the most variation. Previously, studies have analysed the impact of intra- and  
inter-subtype variation on LTR functional activity. Mostly these studies have addressed the impact of 
subtype specific differences on LTR driven gene transcription as well as the effect of NF-кB copy 
number on viral gene transcription only during chronic phase of infection where the virus has already 
diversified (Bachu et al., 2012, Jeeninga et al., 2000). Here, we assessed the basal and Tat induced 
patient derived LTR transcription activity of viruses obtained from 14 patients. The patient derived 
LTRs were cloned upstream of the luciferase gene present in the pGL3 Basic vector and the recombinant 
plasmids were transfected into Jurkat cells to assess differential LTR activity. A conserved subtype C 
LTR was used as the wild-type or consensus subtype C LTR (WTC-LTR) obtained from the NIH 
Reagents Programme. The WTC-LTR was amplified and cloned into the pGL3 Basic vector followed 
by sequencing. The WTC-LTR sequence was confirmed against the Indian subtype C reference 
sequence. However, the WTC-LTR used in this study only consisted of three NF-кB binding sites.  
 
Firstly, we compared the LTR elements basal level of gene transcription. In the absence of the Tat 
protein, all patient LTRs were functional promoters that demonstrated a low level of gene transcription 
activity (Figure 12A). Though most patient LTR elements demonstrated gene expression levels that 
were comparable to that of the WTC-LTR, in particular, two patient LTR elements (AS02-802 and 
AS03-268) demonstrated levels of basal gene transcription that were below that of the WT-LTR (Wild-
type LTR). Interestingly, these patients contained the Sp1 III G2A mutation with one patient (AS02-
802) also exhibiting an RBE III C6A mutation. This suggests that the Sp1 III G2A mutation in 
combination with other mutations within the core promoter and enhancer region may decrease the basal 
transcriptional activity of the viral promoter. In contrast, we observed 3 patient LTR elements (AS02-
358, AS03-369 and AS01-919) that showed an approximate 3-4-fold higher level of basal gene 
expression when compared to the WTC LTR promoter. These 3 patient LTRs exhibited a Sp1 III A5C 
(patient AS02-358) and Sp1 III A5T and G2A (patient AS03-369 and AS01-919) mutation respectively. 
This further suggest that the Sp1 III A5T mutation in combination with other mutations within the LTR 
may enhance the basal transcriptional activity of the patient LTRs.  
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Figure 12. Interpatient LTR genetic variability translates to differences in 
transcription activity.  Patient derived LTR-pGL3 basic vector recombinants 
were transfected into Jurkat cells and the luciferase activity was measured after a 
24-hour incubation period. The transfection assay for each sample was performed 
in triplicates therefore the transfection data presented here are illustrative of the 
average relative light units (RLU). (A) Patient derived LTR-pGL3 basic vector 
recombinants were transfected into Jurkat cells alone to measure basal levels of 
gene transcription. (B) The patient derived LTR-pGL3 basic vector recombinants 
were co-transfected into Jurkat cells with a subtype C pcTat BL43.cc. (C)  The 
patient derived LTR-pGL3 basic vector recombinants were co-transfected into 
Jurkat cells with the patients’ autologous tat. However, the autologous tat for 
patient 802 was unavailable for this study therefore, patient 802 was excluded from 
this analysis.  
A 
B 
C 
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LTRD E 
Figure 12 Interpatient LTR genetic variability translates to differences in 
transcription activity Continued.  In addition to the RLU, the Fold change was 
also determined relative to the empty pGL3 vector. (D) Demonstrates the fold 
change for the LTR elements in the presence and absence of Tat. Although we 
examined the variation of the individual patients LTR and Tat activity on 
luciferase expression we then  demonstrated the impact of the specific LTR 
variants (Sp1 III binding site, NF-kB copy  number and TATA Box) on the 
average  luciferase activity in both the absence of Tat (E) and presence of Tat.   
F 
LTR Variant 
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Secondly, we compared the LTR elements gene transcription levels in the presence of a subtype C Tat 
obtained from NIH Reagents Programme (pcTatBL43.cc) and the respective patient autologous Tat 
protein. Irrespective of basal levels of gene transcription, the WT-C Tat protein was able to transactivate 
the majority of patient LTR elements to significantly higher levels of gene transcription (Figure 12B). 
However, 2 patients LTR (AS21-187 and AS03-369) did not show any significant level of 
transactivation and was comparable to the basal level of gene transcription. For patient AS21-187, this 
may be explained by the sequence variation observed in the TATA Box in combination with other 
mutations within the LTR. Patient AS21-187 exhibits the T3A mutation within the TATA Box as 
aforementioned. The alteration from the consensus sequence to the mutated sequence at position 3 has 
been reported to reduce the ability of Tat to bind and transactivate the LTR (Jeeninga et al., 2000, 
Montano et al., 1998). 
 
Table 1. Record of the mutations found within the autologous tat variation and their effect on tat 
function. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AUTOLOGOUS TAT PID 
 
TAT MUTATION 
 
0016 L35Q/ Q39L (Enhancing) 
945 P21A (Reducing) 
Q39L (Reducing) 
Q54R (Reducing) 
703 P21A (Reducing) 
358 P21A (Reducing) 
Q39L (Reducing) 
V4I (Reducing) 
369 Q39L (Reducing) 
1034 S46Y (Reducing) 
268 No reported mutation 
187 P21A (Reducing) 
Y29R (Enhancing) 
458 No reported mutation 
341 L35Q/ Q39L (Enhancing) 
919 P21A (Reducing) 
Q39L (Reducing) 
V4I (Reducing) 
876 P21A (Reducing) 
Y29R (Enhancing) 
 
51 
 
However, where it would be expected that the autologous Tat protein would significantly transactivate 
the LTR to higher levels of gene transcription, the autologous Tat induced levels of gene transcription 
was variable between patients (Figure 12C). This may be possibly explained by the interpatient Tat 
amino acid sequence variability. Also, it is well established that tat variability results in differential 
LTR transactivation activity. The genetic characterization of the autologous Tat amino acid changes 
was previously performed by our group (Mkhize et al 2018., unpublished). However, for the purposes 
of this study, we have highlighted the amino acid substitutions of each autologous tat protein (Table 
1). The autologous Tat mutants characterised as having reducing mutations (Q39L, S46Y, P21A and 
V4I) did not significantly transactivate the LTR and demonstrated gene expression levels that were 
comparable to basal levels of gene transcription. This may be explained by the Tat protein mutations 
that may have a reducing effect on the ability of Tat to transactivate the LTR and hence activate 
transcription. In contrast, the autologous Tat proteins having enhancing mutations (L35Q/ Q39L and 
Y29R) significantly transactivated their respective LTRs to higher levels of gene transcription.  
 
 
4.7. Variability within the LTR confers Differential Responsiveness to Extracellular Stimulation 
 
 
We hypothesized that the interpatient LTR genetic varibaiity would confer differential LTR 
responsiveness to extracellular stimulation with TNF-α, PMA, SAHA and Prostratin. Therefore, the 
reponse of the LTR to extracellular stimulation was examined both in the absence of Tat (Figure 13A) 
as well as in the presence of Tat (Figure 13B).  
 
 
The cell activation assay was performed using 12 LTR elements because the autologous Tat protein 
was unavailable for patients AS02-802 and AS01-876 and therefore these two samples were excluded 
from the cell activation assay and analysis. In the absence of Tat, all patient LTR elements responded 
equally well to stimulation with TNF-α and PMA which induced transcription at levels signficnalty 
higher than that of basal gene trasncription. Extracellular cell stimulation with PMA demonstrated the 
strongest response in all patient derived LTRs. However, patient isolates were least responsive to 
extracellular stimualtion with SAHA and Prostratin. Interestingly, 4 out of 12 patients (AS02-0016, 
AS02-945, AS02-1034 and AS21-187) did not respond to SAHA stimulation as they performed at a 
level equivalent to their respective basal level of transcription. 
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Importantly, one patient LTR element (AS21-187) was consistently not responding to stimulation with 
these cell activators except with PMA. Interestingly, we had highlighted that this specific patient (AS21-
187) had exhbited the TATA Box T3A mutation in combination with other muations within the core 
modulatory and core enhancer domain. This highlights that the gentic varibaility within the U3 region 
alters the reponsiveness of the LTR to stimulation in the absence of Tat.  
 
 
In the presence of the patients autologous Tat, the synergistic activation with cell activators resulted in 
signifcnatly higher levels of gene transcription than was observed without Tat transactivation. 
Importantly, the autologous Tat proteins characterised as having reducing muations (Table 1, data from 
a different study in the lab by a PhD student Zakithi Mkhize) demonstrated low levels of Tat induced 
transcription, however, when synergized with the cell activators, the levels of Tat induced transcription 
was signifcantly enhanced. Once again of particular note, one pateint (AS21-187) was not effciently 
resposnive to the synergistic cell stimulation and performed at levels below that of the WT. In all patient 
LTR elements, the synergistic activation with PMA yielded the strongest transcriptional repsonse.  
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Figure 13. Interpatient LTR genetic variability translates to differential transcription activity in the presence of cell stimulants.  Patient derived LTR-pGL3 basic vector 
recombinants were transfected into Jurkat cells followed by stimulation with TNF-α, PMA, SAHA and prostratin after 12 hours of incubation. The luciferase activity was 
measured after a 24-hour incubation period. The transfection assay for each sample was performed in triplicates therefore the transfection data presented here are illustrative of 
the average relative light units (RLU). (A) Patient derived LTR-pGL3 basic vector recombinants were transfected into Jurkat cells alone to measure basal levels of gene 
transcription in the presence of stimulation with TNF-α, PMA, SAHA and prostratin. (B) The patient derived LTR-pGL3 basic vector recombinants were co-transfected into 
Jurkat cells and co-stimulated with the patients’ autologous tat and of the following cell stimulants: TNF-α, PMA, SAHA and Prostratin. However, the autologous tat for patient 
802 was unavailable for this study therefore, patient 802 was excluded from this analysis.  
 
A B 
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4.8. The Impact of LTR Genetic Variation on Viral Load 
 
The impact of LTR genetic variation on viral replication was then assessed by correlating the LTR 
mutants with viral load (Figure 14). At transmission (p= 0.2811), there were no differences observed 
between the mutation at nucleotide position 2 (G2A) of the Sp1 III binding site and viral load(Figure 
14A). Further to that, no differences were observed at one-year post infection (p= 0.8351). Although, 
the Sp1 III A5T mutant exhibited a reduced mean viral load at both transmission (p= 0.3395) and one-
year post infection (p= 0.2214), this was not significantly different (Figure 14B). The TATA Box 
variant was associated with a reduced viral load as expected due to the reduced transcription activity of 
the TAAAA variant (Figure 14C). However, our data showed that the 4th-NF- кB variants, in 
combination with other mutations within the core enhancer and promoter domain, demonstrate a  
reduction in viral load (Figure 14D) Since these were low frequency mutations, the sample size used 
to analyse the TATA Box and 4th NF-кB variants are too small to be conclusive.   
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Figure 14. The association of LTR variants with viral load at transmission and one year post 
infection. Patient LTR elements were seperated into those patients who had the wild type nucleotide 
and those who exhibited the mutant nucleotide of the SP1 III binding site, TATAA box and those who 
had 3 NF-ĸB binding sites compared to those who had 4-NF-ĸB binding sites. Statical analyses was 
performed using Graphpad Prism 5.1 software for Windows, GraphPad Software, San Diego California 
USA, (www.graphpad.com). The paired T-test was used to determine signficance. The mean viral load 
was compared at near transmission and one year post infection. (A) A comparison of the viral load of 
patients exhibiting the wild type G nucleotide and those exhbiting the mutant A nucleotide at position 
2  of the Sp1 III binding site. The mean viral load of patients exhibiting the mutant nucleotide was lower 
than the mean viral load of patients having the wild type nucleotide. However at one year post infection 
there was no significant difference in viral load. (B) A comparison of the viral load of patients exhibiting 
the wild type A nucleotide and those exhbiting the mutant T nucleotide at position 5 of the Sp1 III 
binidng site. The mean viral load of patients having the mutant nucleotide was lower than the mean 
viral load of patients having however this was not signficant. (C) A comparison of the viral load of 
patients exhibiting the wild type T nucleotide and those exhbiting the mutant A nucleotide at position 
3 of the TATAA box. (D) A comparison of the mean viral load of patients exhibiting the 3rd-NF-ĸB 
binding and those patients having the 4th-NF-кB binding site.  
 A B 
C D 
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4.9. Correlation of LTR Transcriptional Activity with Clinical Markers  
 
Basal LTR activity and autologous Tat induced gene expression was correlated with clinical markers 
such as viral load and CD4 count and statistical significance was assessed using a linear regression to 
determine the correlation coefficient (Figure 15 Panel 1 and 2). At transmission and one-year post 
infection, there was no significant correlation between basal LTR activity and viral load (transmission: 
p= 0.9256, r= 0.027, one-year post infection: p= 0.4633, r= 0.21) (Figure 15 Panel 1: A and C). Further 
to that, we did not identify a significant correlation between basal LTR activity and CD4 count at 
transmission (p= 0.3056, r= 0.30) and one-year post infection (p= 0.7252, r= 0.10) (Figure 15 Panel 1: 
B and D). The autologous Tat induced LTR activity demonstrated a positive correlation with viral load 
at transmission (p= 0.0134, r= 0.66) however within one-year of infection this correlation was weakened 
and was not significant (p= 0.3905, r= 0.26) (Figure 15 Panel 2: A and C). Although, the autologous 
tat induced activity showed a negative correlation with CD4 count at transmission (p= 0.2188, r= 0.37) 
and one-year post infection (p= 0.1659, r= 0.41), this was also not significant (Figure 15 Panel 2: B 
and D). The relationship between the basal and Tat induced LTR activity was weak and therefore did 
not show a strong prediction for the clinical markers.  
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__________________________________________________________________________________ 
 
Figure 15. No correlation of LTR activity with markers of disease progression. Linear regression 
analyses were performed using Graphpad Prism 5.1 software for Windows, GraphPad Software, San 
Diego California USA, (www.graphpad.com)to determine a correlation between LTR basal activity 
measure in RLU and viral load as well as CD4 count at transmission and one-year post infection. Panel 
A: demonstrates the correlation between basal LTR activity and viral load and CD4 count at 
transmission (left) and one-year post infection (right). Panel B: demonstrates the correlation between 
tat induced LTR activity and viral load and CD4 count at transmission (left) and one-year post infection 
(right). 
Panel 1 
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Transmission 
p=0.9256 
r= 0.027 
One-year post 
infection 
p=0.4633 
r= 0.21 
Transmission 
p=0.3056 
r= 0.30 
One-year post 
infection 
p=0.7252 
r= 0.10 
One-year post 
infection 
p=0.3905 
r= 0.26 
One-year post 
infection 
p=0.1659 
r= 0.41 
Transmission 
p=0.0134 
r= 0.66 
Transmission 
p=0.2188 
r= 0.37 
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CHAPTER 5: DISCUSSION 
 
It was hypothesized that the HIV-1C T/F viruses LTR genetic variation may have an impact on the 
viruses’ transcriptional activity and may influence disease outcome in a cohort from South Africa. The 
data presented in this study demonstrates that the LTR genetic variation may impact the transcriptional 
activity of the virus however there was no distinct impact on disease progression. 
 
A previous study reported inter-subtype LTR variation within the LTR element (Jeeninga et al., 2000) 
while the other studies reported intra-subtype, HIV-1 subtype C LTR variation (Boullosa et al., 2014, 
Jeeninga et al., 2000). However, this variation has been reported during chronic infection where the 
virus has already diversified due to virus own error-prone Reverse Transcriptase. Therefore, in this 
study we undertook to study HIV-1 subtype C genetic variation at or near (within 28 days of infection) 
transmission and diversity by one-year post infection.  
 
Interestingly, our data demonstrate that sequences obtained from a total of 25 people living with acute 
HIV-1 infection were classified as  HIV-1 subtype C virus (Figure 9). Sequences obtained at or near 
transmission from the same patient formed interpatient clusters with limited branch length differences, 
a stronger bootstrap support for  all subjects and showed no evidence of relatedness of viruses from 
different patient participants (Figure 8). Therefore our data demonstrate that the T/F viruses LTR 
exhibits intra-subtype variation at transmission and limited evolution by one year post infection. In 
addition, Contrary to a study by Carlson et al., and colleagues (2014) who reported that the consensus 
like sequences for gag, pol and env were selected for at transmission, our data show that the T/F viruses 
LTR element does not exhibit a consensus like at transmission. 
 
 
It is widely established that HIV-1 subtype C has expanded to contain a 3rd NF-кB binding sites 
compared to most subtypes, which have only 2 NF-кB binding sites and subtype AE that has one NF-
кB binding site. Interestingly, the data from our study demonstrate that 100% of patient derived LTR 
sequences from the South African cohort contain 3 intact NF-кB binding sites. However 8% of pateints 
contained a 4th NF-кB binding site and 12% of patients contained the NF-кB like binding site (Figure 
9). This observation is consistent  with previous genetic characterization of the South African subtype 
C, which showed that 86% of patient  derived LTR sequences exhibited the 3rd NF-кB binding site 
while 14% of patient isolates had a NF-кB like site (Scriba et al., 2002). These data demonstrate that 
there is no evidence suggesting that HIV-1 subtype C viruses that contain the 4th NF-кB binding site in 
South Africa are expanding.  
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Other studies from outside South Africa have also reported that HIV-1 subtype C viruses that contain 
the 4th NF-кB binding site as well as the NF-кB-like binding sites exists (Bachu et al., 2012, Boullosa 
et al., 2014, Hunt et al., 2001, Scriba et al., 2002). Contrary to the epidemic in South Africa, genetic 
characterization of the patient derived HIV-1 subtype C LTR in the other part of the world has depicted 
the rise of the 4th NF-кB and NF-кB  like binding sites  in India, Brazil, Mozambique and South Africa 
(Bachu et al., 2012, Boullosa et al., 2014, Scriba et al., 2002). Bachu et al., (2012) reported that the 
HIV-1 subtype C containing the 4th NF-кB was expanding in India thus becoming a dominant strain. 
These data suggest that the acquisition of the 4th additional NF-кB binding site confers a replicative 
advantage thus permitting its rapid expansion throughout India (Bachu et al., 2012).  However, as 
aforementioned our data do not show evidence of HIV-1 subtype C viruses containing the 4th NF-кB 
binding site expanding in South Africa. 
 
 
The occurrence of NF-кB like sites occurred in three out of twenty five (12%) patients, of which the 
NF-кB like binding site (GGGCGGTCC) found in patient AS903-036, referred to as 369 in this thesis  
was previously reported in a South African isolate TV008 (Scriba et al., 2002) (Figure 9). More 
recently, another study by Obasa et al 2019 showed that the canonical sequence of NF-кB had mutated 
to exhibit  the sequence of the 4th NF-кB binding site in 6% of sequences within NF-кB II and in 1% of 
sequences within NF-кB, while the majority of the sequences exhibited the intact canonical sequence 
within NF-кB II (n=50; 72%) and NF-кB I (n=55; 87%) binding sites (Obasa et al., 2019). On the other 
hand, 49/63 (78%) exhibited the intact subtype C specific NF-кB (C- NF-кB) binding site (Obasa et al., 
2019). Our study demonstrate the NF-кB I and NF-кB II binding sites from patient derived LTR 
sequences were conserved at transmission or near transmission and at one year post infection time points 
from all 25 PLHIV-1 (Figure 9).  
 
 
The Sp1 binding sites are reported as conserved elements with the Sp1 III binding site demonstrating a 
greater degree of variability in comparison to the Sp1 I and Sp1 II binding site (Mbondji-Wonje et al., 
2018, McAllister et al., 2000, Nonnemacher et al., 2004, Zhang et al., 1997). Consistent with this, our 
data demonstrated that Sp1 I and Sp1 II sequences were conserved while the Sp1 III sequence was the 
most variable (Figure 9). While Scriba et al., (2002) reported that the Sp1 II site was most conserved, 
our data show that the Sp1 I is more conserved than the Sp1 II binding site which is concordant with 
preceding studies (Mbondji-Wonje et al., 2018, McAllister et al., 2000). The Sp1 III functional capacity 
is dependent on the guanine residue at position 4 of the Sp1 III binding site. A single nucleotide 
modification at position 4 can hinder Sp1 binding and significantly weaken the tat-induced 
transactivation of the LTR (Berkhout and Jeang, 1992, Das et al., 2011, Kamine et al., 1991, McAllister 
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et al., 2000). The South African subtype C remains very well conserved at position 4 of the Sp1 binding 
site thereby possibly conserving optimal Sp1 factor interaction and binding.  
 
The Sp1 III binding site exhibited variability specifically at position 2 and position 5 (Figure 9). One 
study that assessed the incidence of nucleotide changes within the subtype B Sp1 binding sites showed 
that the Sp1 III binding site had a 30% average non-consensus frequency at position 5 (McAllister et 
al., 2000). Further to that, this same study demonstrated that single nucleotide changes of the Sp1 III 
binding site can impair basal gene transcription (McAllister et al., 2000). The HXB2 Sp1 III sequence 
that is mutated at position 5 from a C-to-T nucleotide (GAGGCGTGGC  GAGGTGTGGC) was 
shown to reduce Sp1 binding efficiency (Nonnemacher et al., 2004). Furthermore, this mutation was 
shown to increase in frequency during disease progression and be associated with disease progression 
(Nonnemacher et al., 2004). Similarly, the subtype C Sp1 III presented in this study exhibits the 5T 
mutation (GGGGAGTGGT  GGGGTGTGGT) which is in agreement with previous studies 
(Mbondji-Wonje et al., 2018, McAllister et al., 2000, Shah et al., 2014). 
 
 
 
This study did not find a significant difference between the mean viral loads of patients exhibiting the 
Sp1 III 2G nucleotide and those having the Sp1 III 2A nucleotide at one-year post infection (Figure 
14). This may suggest that the Sp1 III G2A mutation may not be a predictor of disease outcome (viral 
load) during acute infection. The nucleotide substitution at position 5 of the Sp1 III binding site was 
previously associated with reduced activity (Nonnemacher et al., 2004). In our study, The Sp1 III: A5T 
identified within the Sp1 III binding site in this cohort showed decreased viral load at transmission and 
one-year post infection. This may be suggesting that the Sp1 III binding sites with nucleotide 
substitutions at position 5 may result in decreased transcription activity and hence reduced viral load. 
The effect of Sp1 factor binding has not been examined for subtype C viruses in South Africa. Thus, 
presenting a limitation to this study in that we did not examine the binding affinity of the Sp1 proteins 
for the mutated Sp1 III binding site. However, based on the previous findings by Nonnemacher et al., 
(2004), it is likely that the subtype C Sp1 III: A5T mutation may present with reduced binding affinity 
for the Sp1 proteins and hence reduced activity of the Sp1 III binding site.  
 
Multiple studies have previously examined the functional activity of the LTR of subtypes A through G 
as well as the functional activity of viral variants differing in NF-кB copy number (Bachu et al., 2012, 
Jeeninga et al., 2000, Montano et al., 1998). In this study we specifically examined the functional 
activity of 14 patient LTR elements using a transfection assay in vitro. Even in the presence of genetic 
variation, all patient LTR elements were able to drive basal levels of gene transcription, although at 
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varying levels (Figure 12A). Notably, patients AS02-0802, AS03-0268 and AS02-876 demonstrated a 
reduced basal gene transcription that was below that of the consensus, referred to as wild-type sequence. 
Interestingly, these two patients both shared a Sp1 III- G2A mutation. While those patients having either 
a Sp1 III- A5T mutant or a co-mutation of Sp1 III- A5T and G2A performed equally well as the wild 
type or 3-4-fold higher than the wild type such as in patient isolates AS02-358, AS03-369, AS02-1034 
and AS01-919. This data may indicate that having a Sp1 G2A mutation only may impair basal gene 
transcription thereby reducing the transcription and replicative fitness of the virus. Therefore, the fold 
differences in basal gene transcription may be significant in understanding the viral fitness of each 
patient.  
 
 
In vivo, viral transcription is dependent on the ability of the viral protein, Tat to transactivate the LTR 
transcription ability or activity in order to fully transcribe the provirus genome. Therefore, we assessed 
the ability of the LTR to be transactivated by the HIV-1 subtype C consensus Tat in vitro. The subtype 
C pcTat that contains consensus Tat sequence was used. Our data show that irrespective of the level of 
basal gene transcription, the subtype C consensus Tat was able to transactivate all patient derived LTRs 
to significantly increase the level of gene transcription. Our data demonstrate that although the Sp1 
G2A mutant may have impaired basal LTR activity, it did not hinder the ability of Tat to transactivate 
the LTR as compared to the previously described Sp1 III mutation at position 4 (Miller-Jenson et al., 
2013). 
 
 Patient AS21-187 did not show any significant transactivation (with both the WT subtype C Tat and 
autologous Tat) compared to the wild type subtype C (Figure 12A and B) and this may be as a result 
of the T3A mutation within the TATA Box (TATAA  TAAAA) along with other mutations within 
the patients LTR.  The TATA box is located 28 base pairs upstream from the transcription start site in 
the U3 region (Berkhout and Jeang, 1992). The Tata binding protein (TBP) together with several 
transcription factors form a TFIID complex binds to the TATAA sequence to initiate transcription (Van 
Opijnen et al., 2004). The change from a T nucleotide at position 3 to an A nucleotide significantly 
impairs the interaction between the TATA box sequence and TBP-TFIIB complex consequentially 
impairing the recruitment of RNA polymerase II (Van Opijnen et al., 2004). Therefore, there is complete 
requirement of a T nucleotide at the 3rd position of the TATA element. The mutated TATA box 
(TATAA  TAAAA) sequence impairs the ability of the LTR to initiate transcription. This therefore 
demonstrates that LTR genetic variation impacts LTR transactivation and HIV-1 pathogenesis.  
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An indication of the ability of the LTR to drive viral gene transcription in vivo may be imperative in 
determining the rate of disease progression as well as the shift between latent and productive infection. 
The assessment of the tat-induced gene transcription using the patient’s autologous Tat protein 
permitted the evaluation of LTR activity in combination with tat protein variability (Figure 12C). 
Single amino acids alterations within the Tat protein can impair its ability to either recruit P-TEFb or 
phosphorylate RNA polymerase II resulting in impaired transcription capacity (Dey et al., 2012). 
However, the presence of single amino acid changes can also enhance Tat recruitment of the TBP and 
P-TEFb. the autologous tat transfection data presented here demonstrate that tat genetic variation can 
also significantly impair LTR transactivation in the case of the P21A, Q39L and V4I tat variants. The 
combination of LTR and Tat genetic variation results in differential functional activity of the LTR.  
Patients that have suppressed LTR transactivation activity may be more likely to shift from a productive 
infection to a latent infection whereas those patients that have significantly enhanced transactivation 
activities are more likely to transition to a productive infection rather than a latent state.  
 
 
Previously, it was demonstrated that the 4-NF-кB variants have higher gene reporter expression in 
comparison to a 3-NF-кB LTR (Bachu et al., 2012). In this study, a comparison of the transcription 
capacity of variants containing 3-NF-кB binding sites versus the 4th NF-кB variants showed that the 3 
NF- кB variants demonstrated higher transcriptional activity (Figure 12 A). It is noted that three 3-NF-
кB variants exhibited an approximate 1-2-fold higher transcription capacity than the 4-NF-кB variant 
(patient AS02-1034 and AS21-187) during basal and subtype C consensus Tat induced transcription. 
The inconsistency of the 4th NF-кB variants to achieve higher gene reporter expression above all patient 
LTRs may be a possible consequence of the variability in other regions of the LTR such as the Sp1 III 
A5T mutation and TATA Box T3A mutation.  
 
Furthermore, our data demonstrate that irrespective of low basal gene transcription activity, 
extracellular activation with TNF-α and PMA stimulates the LTR (in the absence of Tat) to significantly 
higher levels of gene transcription (Figure 13A). The patient LTR elements were more strongly 
activated by PMA as compared to TNF-α, SAHA and prostratin. Interestingly, regardless of the level 
of Tat-responsiveness, all patient isolates demonstrated a stronger response to extracellular stimulation 
with PMA than with TNF-α (Figure 13B). The Tat (autologous) induced transcription activity was 
significantly enhanced in the presence of PMA and TNF-α however, all isolates demonstrated stronger 
responsiveness to PMA than TNF-α.  Patient isolates with a high level of Tat-responsiveness (358, 
1037, 268, 458 and 341) demonstrated an equal responsiveness to extracellular stimulation with SAHA 
and Prostratin.  
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Interestingly, patient isolates that were less responsive to the autologous Tat (1034, 187 and 919) were 
more responsive to stimulation with SAHA and Prostratin (Figure 13B). This therefore may 
demonstrate that there is variation among the patient LTRs in which isolates that are least responsive to 
the autologous Tat may respond better to stimulation with SAHA and Prostratin than patient isolates 
that have higher levels of Tat responsiveness. A block in activity of the LTR and autologous Tat 
combined was overcome by extracellular stimulation and responded strongly to activation with PMA.  
Interestingly, the interpatient LTR variability resulted in variability in the transcriptional activity of the 
various LTR elements under stimulation within TNF-α and PMA. This variability between patients may 
suggest that each patients LTR is subject to varying levels of activation and the activation potential of 
each LTR element differs between patients.  
 
Our data suggest that targeting the LTR in a therapeutic setting of latency reversal, would require that 
the genetic variability of each patients LTR be taken into account since this may have an impact on the 
activation potential of the LTR. The majority of the patients LTR (96%) responded equally well to 
extracellular stimulation except for patient AS21-187 that did not show a significant increase in both 
basal and autologous Tat induced activity. This may propose that all patient LTR elements may be 
activated via the same mechanism when stimulated with PMA but the interpatient LTR variability may 
be the source for the observed differences in the levels of responsiveness. Patient AS21-187 exhibited 
a 1-2-fold transcription activity following stimulation with TNF-α and PMA compared to the majority 
of patient LTRs that were successfully activated to approximately 50-100-fold. This further emphasizes 
that every patients LTR may respond differently to extracellular stimulation and LTR variability may 
impact the activation potential of the LTR. 
 
The LTR basal transcription did not correlate with viral load and CD4 count at or near transmission and 
one-year post infection. However, the autologous Tat induced transcription strongly correlated 
positively with plasma viral load at transmission. In addition, autologous Tat induced transcription did 
not  corelate with a decline in CD4 cell count at or near transmission and one-year post infection. Taken 
together our data demonstrate that during acute infection the autologous Tat induced LTR transcription 
contributes to an increase in plasma viral load. Therefore, during acute infection, the autologous Tat 
induced LTR activity may be a predictor for disease outcome (viral load).  
 
 
In conclusion, our data demonstrates that the core enhancer and core promoter region of the LTR is 
relatively well conserved in relation to the consensus (wild type) LTR, nonetheless there was notable 
variation within the RBE III site, Sp1 III site and TATA Box.  Furthermore, specific LTR variants may 
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be associated with greater capacity of the LTR to drive viral gene expression while other variants may 
be associated with a reduced capacity for driving viral gene expression. Interestingly, the TATA Box 
T3A mutation in combination with other mutations in the LTR demonstrated that LTR variability within 
the core promoter may significantly impair Tat induced LTR activity. However, further studies 
involving site directed mutagenesis may be required to assess the impact of the RBE III (C6A), Sp1 III 
(G2A and A5T) and TATA box mutants (T3A) alone and in combinations with other muations wihtin 
the South African subtype C LTR. We further show that the 3rd NF-кB binding site variants dominate 
the 4th NF- кB binding site variants in this South African cohort therfore, our data suggest that there is 
no evidence for the expansion of the 4th NF-кB variants in South Africa.  
 
 
The differential interpatient basal gene expression may plausably be as a result of the variation within 
the RBE III site, Sp1 III site and TATA box acting in combination with other mutations present within 
the LTR. In additon our data demonstrated that the transcription acitivity of the LTR variants exhibit 
differential responsvieness to extracellular stimulation with TNF-α, PMA, SAHA and prostratin. 
However, the majority of LTR variants were shown to be most responsive to stimulation with PMA. 
Furthermore, the reuslts presented here further showed that the TATA Box T3A (TAAAA) variant, in 
combination with other mutaions that resulted in reduced LTR activity, was marginally induced when 
stimulated with PMA.   
 
The interpatient LTR variability may have an impact on viral transcription and may impact viral fitness. 
Taken together, our data suggests that variation within the LTR mayimpact the transcriptional activity 
of the T/F virus. The data from this study may contribute to understanding the role of the LTR in 
establishing latency during acute infection.   
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